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ABSTRACT 
The purpose of this disquisition was to determine knowledge, beliefs, attitudes, and 
barriers of college-age students at North Dakota State University (NDSU) related to the human 
papillomavirus (HPV) and the vaccine used to prevent certain strains of the virus.  HPV is the 
most common sexually transmitted infection in the United States, with the highest rates of 
infection occurring in the late teens to early twenties (CDC, 2015b).  Therefore, there is a need to 
educate college age students about HPV and how to protect themselves from acquiring HPV.  An 
intervention was designed to address the following clinical question: Will the provision of HPV 
education to college students, ages 18-26, increase HPV knowledge, vaccine intent, and the 
number of student HPV vaccinations within six months at NDSU?   
Project intervention consisted of two components: reaching out to NDSU students at the 
annual Sex Positivity Expo and members of two NDSU organizations, the Women’s Activist 
Organization, and Violence Prevention Educators.  Students were first instructed to take a pre-
test to establish baseline HPV knowledge, beliefs, attitudes, and barriers.  Following the pre-test, 
students were instructed to watch a short educational video about HPV and the HPV vaccine.  
Students then completed a similar post-test to assess if there were increases in basic HPV 
education, and changes in beliefs, attitudes, barriers, or intent to vaccinate.  
Results between pre-and post-survey data indicated an increase in both HPV knowledge 
and intent to vaccinate.  An increase in vaccination rates was not noted, although of the 30 
student participants, 70% had completed the HPV vaccine series prior to education. Questions 
addressing attitude indicated an increase in motivation to maintain a healthy lifestyle.  Questions 
addressing belief indicated students believed they would be protected from the most cancer-
causing strains of HPV. Fifty percent of students indicated they believed themselves at risk for 
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acquiring HPV.  Questions addressing barriers indicated the following were not barriers:  
healthcare coverage, work and school, and their provider offering them the chance to begin the 
HPV vaccine series.  The only barrier identified with a slight increase in mean of 0.08 indicated 
the cost of the vaccine series to be a concern. 
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CHAPTER 1. INTRODUCTION 
Background 
Human papillomavirus (HPV) is the most common sexually transmitted infection (STI) 
in the United States today with over 150 related viruses (CDC, 2015a).  The prevalence of the 
virus is so great the Centers for Disease Control and Prevention (2015a) has predicted nearly all 
sexually active men or women will acquire HPV at some point throughout their lifetime. Today, 
one out of four people in the United States are infected with HPV and the CDC predicts nine out 
of ten people will acquire the HPV infection at some point throughout their lifetime (CDC, 
2015d, 2015e).  Approximately 79 million Americans are infected with the HPV virus and 
roughly 14 million more acquire the infection every year (CDC, 2015d). Certain strains of HPV 
are known to cause warts (papillomas), which is what HPV is named for, and there are over 40 
strains of HPV known to infect both male and female genitals (CDC, 2015a). 
HPV is transmitted by skin-to-skin contact in vaginal, anal, or oral sexual encounters 
from a person who is a carrier of the virus (CDC, 2015a). Spread of the virus is most common 
throughout the late teens and early 20s (CDC, 2015b).  The virus can be passed even when the 
infected person does not present with any active signs or symptoms, with onset of symptoms 
developing sometimes years after a person is infected (CDC, 2015a). While a majority of people 
will be exposed to HPV at some point in their lifetime, individuals may not even be aware 
because the body is naturally able to fight certain strains of the virus.  
Although most HPV infection remains asymptomatic, some strains do result in various 
clinical manifestations including genital warts, cervical cell abnormalities, anogenital squamous 
cell cancers, oropharyngeal cancers, and recurrent respiratory papillomatosis (CDC, 2013).   The 
two most significant manifestations are considered to be visible genital warts and cervical 
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abnormalities detected by Papanicolaou (Pap) tests (CDC, 2013).  Genital warts have four 
classifications: Condylomata acuminata, smooth papules, flat papules, and keratotic warts (CDC, 
2013).  Symptoms associated with genital warts in various locations include dyspareunia (painful 
intercourse), pruritus (itching), burning, hematuria (blood in the urine), discharge, obstruction of 
the birth canal (due to increased growth during pregnancy), anal bleeding, or impaired urinary 
stream (CDC, 2013). People who have weakened immune systems are less likely to fight off 
certain strains of HPV and subsequently, are at higher risk to develop sequelae associated with it 
(CDC, 2016a). Immune system responses have also been examined to conclude determinants of 
naturally acquired protection including multiple factors such as antibody levels, antibody 
response, and serological responses (Franceschi & Baussano, 2014).  
The majority of cervical, vaginal, penile, anal, and oropharynx cancer occur due to HPV 
strains the body is not able to clear (CDC, 2015b).  The CDC reports there are 38,793 new 
cancers diagnosed annually which are found in body parts where HPV is often found, with HPV 
being responsible for 30,700 of these cases (CDC, 2016b).  Overwhelmingly, HPV is the 
causative factor in 79% of those cancers (CDC, 2016b).  Cervical cancer is listed as the most 
common HPV-associated cancer for women, while oropharyngeal cancers (posterior throat, 
including the base of the tongue and tonsils) are the most common for males (CDC, 2016b). 
Eleven thousand women are annually diagnosed with cervical cancer, with an estimated 4,400 
dying every year (CDC, 2015c).  Annually in the U.S., about 400 males develop cancer of the 
penis, 1,500 develop HPV-related cancer of the anus, and 5,600 develop oropharynx cancer 
(although this can also be related to tobacco or alcohol use) (CDC, 2012a). 
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Natural History and Epidemiology 
HPV is a double-stranded deoxyribonucleic acid (DNA) virus belonging to the 
Papillomaviridae family (CDC, 2015j; CDC, 2013).  The virus infects the basal epithelium lining 
of the skin, stimulating cellular proliferation (CDC, 2015j; CDC, 2013). There is a difference 
between males and females for how the virus affects the genital tract, affecting mucous 
membranes in females and keratinized epithelia in males (Franceschi & Baussano, 2014). Each 
strain of the virus is genetically distinguished by the outer capsid protein L1 with the majority of 
strains targeting the cutaneous epithelium, causing skin warts (CDC, 2015j). Approximately 40 
HPV types target mucosal epithelium which are epidemiologically associated with cervical 
cancer (CDC, 2015j).  Low-risk, or nononcogenic HPV strains (such as HPV-6 and 11) are 
known to cause 90% of genital warts and also laryngeal papillomas, which are benign (CDC, 
2015j).  Low-risk HPV strains have also been known to cause respiratory tract warts in children 
(juvenile-onset recurrent respiratory papillomatosis, or RRP) (CDC, 2012b).  High-risk strains 
(such as HPV-16 and 18) are known to cause a range of sequelae including both low and high-
grade cervical changes and anogenital cancers (CDC, 2015j).  HPV is linked to 90% of anal 
cancers, 71% of vulvar/vaginal/penile cancers, and 72% of oropharyngeal cancers (CDC, 2015j). 
HPV-related high-grade cervical cell changes are the predecessors to cancer, and have been 
linked to 99% of cervical cancers (CDC, 2015j).  HPV type 16 is linked to about 50% of cervical 
cancer, while types 16 and 18 combined account for approximately 70% (CDC, 2015j). 
According to the American Cancer Society (ACS) in 2014, cervical cancer was previously the 
most common cause of death for women in the United States; however, the death rate has been 
reduced by more than 50% within the last 40 years with increased utilization of the Pap test in 
health care practice.  While the majority of cervical cancer is found in women under the age of 
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50, and rarely found in women under 20, a small percentage (15%) is found in women over the 
age of 65 (ACS, 2014). 
 HPV is an extremely infectious virus, with the incubation process ranging anywhere from 
three weeks to several months for genital warts to appear, several months to years for adverse 
changes in cervical cells to occur, and decades for cervical cancers (CDC, 2013a).  The median 
amount of time for detection of new cervical cancers to appear is eight months, but this number 
is variable (CDC, 2013a). The CDC estimates that 70% of new infections clear within the first 
year and 90% clear within two years (CDC, 2013a).  The DNA clearance of HPV is likely due to 
gradual onset of a more effective immune response (CDC, 2013).  
Persistent HPV infection which is not cleared from the body ultimately results in cervical 
intraepithelial neoplasia (CIN), ranging from CIN1 (low-grade) to CIN2 or CIN3 (higher-grade) 
(CDC, 2015j).  CIN1 has a good chance of spontaneously resolving within the first few years of 
infection, but if it does not clear from the body will result in higher-grade CIN2 or 3 which can 
be precursors to cancer if they remain undetected and untreated (CDC, 2015j).  Important to 
note, some high-grade CIN naturally regresses on their own (CDC, 2015j).   
Risk factors related to infection with HPV are predominantly related to sexual history 
including young age, number of pregnancies, genetic factors, smoking, oral contraceptive use, 
poor nutrition, and lack of male partner circumcision (CDC, 2015j; CDC, 2013). Certain types of 
sexual behavior also put a person at greater risk, including an increasing numbers of sex partners 
throughout one’s lifetime, first sexual intercourse occurring at a young age, as well as high risk 
behaviors individuals may engage in during sexual activity (CDC, 2013).  Engaging in sexual 
activity with partners who have had multiple other sexual partners has been shown to increase 
risk (CDC, 2013). Immunosuppression increases the risk of HPV detection, such as persons with 
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HIV, those on dialysis, and those who have had a kidney transplant (CDC, 2013).  The biggest 
risk factor for precancerous and cancerous cervical cell changes is persistent infection with 
oncogenic HPV-types (CDC, 2013).  Risk factors for persistent infection include advanced age, 
certain HPV types, and immune suppression (CDC, 2013). Ways to avoid acquiring health 
problems associated with HPV include cervical cancer screenings and getting vaccinated (CDC, 
2016a).   
Methods of HPV prevention include using condoms and being in a mutually 
monogamous relationship (CDC,2016a).  Abstaining from sexual activity is the most certain way 
of preventing any HPV infection (CDC, 2015j). Although condoms are an efficient prevention 
method, effectively lowering the chances of contracting HPV, the virus is also able to infect 
areas not covered by a condom through skin to skin contact or nonpenetrative sexual activity 
(CDC, 2016a; CDC, 2015j).  Therefore, a condom cannot be considered to fully protect against 
acquiring the virus.  According to the CDC (2015j), studies indicate that infection happens soon 
after sexual activity begins; one study involving college women determined a 40% rate of 
infection 24 months after the first sexual encounter (CDC, 2015j). Another mode of transmission 
includes a nonsexual route from a woman to an infant during passage through the birth canal 
(CDC, 2015j).  
Laboratory diagnosis of HPV is completed through use of clinical samples, with HPV 
detection assays having a great amount of variability in sensitivity and type specificity (CDC, 
2015j).  Recognition of the virus depends on the method of clinical sample collection as well as 
anatomy of the sample region (CDC, 2015j).  Multiple HPV tests approved by the FDA have 
successfully identified high-risk HPV strains (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
66, 68) (CDC, 2015j).  Pap tests and liquid-based cytology are used today for HPV screening 
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(CDC, 2015j).  Cervical cancer screening should be done every three years beginning at the age 
of 21 through the age of 65 or every five years with HPV testing (for ages 30-65) according to 
organizations such as U.S. Preventive Services Task Force (USPSTF), American Cancer Society 
(ASC), American Society for Colposcopy and Cervical Pathology (ASCCP), and the American 
Society for Clinical Pathology (ASCP) since 2012 (CDC, 2015j).                                
HPV Vaccine Information 
Immunizations are of great importance to preventative care measures in health care 
today.  Through following routine immunization schedules, parents can protect their children and 
the community from dangerous disease processes which used to be prevalent, and some that still 
are (such as HPV), throughout populations.  Immunizations are also utilized to prevent certain 
types of cancers throughout one’s lifetime.  HPV has been linked to the two most common types 
of cervical cancer, squamous cell carcinoma and adenocarcinoma (CDC, 2015j).  
Three vaccines have been approved and recommended by the Advisory Committee on 
Immunization Practices (ACIP) and the U.S. Food and Drug Administration (FDA) for the 
prevention of HPV: Gardasil 9, Gardasil, and Cervarix (USFDA, 2015; CDC, 2015f).  Cervarix 
is no longer available in the United States today due to the low market demand (Mulcahy, 2016). 
All three types of vaccinations have been shown to prevent cervical cancer in women (HPV, 
2012). Gardasil 9, the newest available vaccine, was licensed for distribution in 2014 and 
protects against 9 strains (9-valent or 9vHPV) of the HPV virus compared to quadrivalent 
Gardasil (protecting against 4 strains, or 4vHPV), and previously used bivalent Cervarix 
(protecting against 2 strains, or 2vHPV) (CDC, 2015g).  The 2vHPV vaccine targeted HPV types 
16 and 18; 4vHPV targets the HPV types 6,11, 16, and 18; 9vHPV targets the same HPV types 
as the 4vHPV, in addition to 31,33,45,52, and 58 (Markowitz et al, 2016).  While there are over 
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150 types of HPV with over 40 cancer-causing HPV types, seven are considered to be “high 
risk” (16, 18, 31, 33, 45, 52, and 58) (NIH, 2015).  Repeated exposure to the high-risk types can 
lead to cellular changes with the probability of progression to cervical, anal, penile, vaginal, 
vulvar, or oropharyngeal cancer (NIH, 2015).  
Table 1 
HPV Vaccines 
 Bivalent/2vHPV (Cervarix) Quadrivalent/4vHPV (Gardasil) 9-valent/9vHPV (Gardasil 9) 
Manufacturer GlaxoSmithKline Merck Merck 
Year Licensed October 2009 – females June 2006 – females; October 2009 - 
males 
December 2014 – males and females 
HPV types in 
vaccine 
16 and 18 6, 11, 16, and 18 6, 11, 16, 18, 31, 33, 45, 52, and 58 
Adjuvant in 
vaccine 
AD04: 500 µg aluminum 
hydroxide 
50 µg 3-0-desacyl-4’-
monophosphoryl lipid A 
AAHS: 225 µg amorphous aluminum 
hydroxyphosphate sulfate 
AAHS: 500 µg amorphous aluminum 
hydroxyphosphate sulfate 
Recommended 
for… 
Females ages 11-12 
Females ages 13-26 who have 
not been previously vaccinated 
(No longer available in the US) 
Females and males ages 11-12 
Females ages 13-26 and males ages 13-
21 who have not been previously 
vaccinated 
Unvaccinated males ages 22-26 who 
have sex with men or who are 
immunocompromised 
Females and males ages 11-12 
Females ages 13-26 and males ages 
13-21 who have not been previously 
vaccinated. 
Unvaccinated males ages 22-26 who 
have sex with men or who are 
immunocompromised 
Contraindicated 
for… 
People with hypersensitivity to 
latex 
People with hypersensitivity to yeast People with hypersensitivity to yeast 
(CDC, 2015c) 
The CDC has recently changed the recommendations for HPV vaccines to be 
administered as a two-dose series at least six to 12 months apart starting at the ages of 11 and 12, 
although can be started as early as age 9 (CDC, 2016d).  For those ages 15-26 years old, the 
series continues to be administered as a three-dose series (0, 1-2 months, 6 months) (CDC, 
2016c; CDC, 2016d). If a person waits longer than recommended between shots (months or 
years), the vaccine series can still be completed without having to be restarted (CDC, 2015k). 
Booster doses are not recommended at this time by the Advisory Committee on Immunization 
Practices (ACIP) for the HPV vaccine series (CDC, 2015k).  The 2vHPV vaccine was used for 
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females only, while the 4vHPV and 9vHPV vaccines are still available to be used for both males 
and females. A catch up vaccination is also available for adolescents ages 13-18 years old (CDC, 
2016c).  The 9vHPV vaccine has been approved for use up to the age of 26 (CDC, 2015e).  The 
HPV vaccine is not recommended over the age of 26 due to the lack of protection from HPV-
related diseases after this age (CDC, 2017a). The best way to prevent a woman over age 26 from 
developing cervical cancer is to perform recommended screening tests (CDC, 2017).  One of the 
goals of treatment is to vaccinate pre-teens and adolescents before any sexual activity begins.  
Early vaccination has been shown to be beneficial because the immune response is two to three 
times greater in pre-teens (ages 9-11) when compared to teenagers and young adults (15-25) 
(NY, 2012). The way to achieve the greatest benefit from the vaccine is to receive all three doses 
in the vaccination series if over the age of 15, and both doses six months apart if age 14 or under 
(CDC, 2017).  The highest immune responses observed after completion of a three-dose 
vaccination series show elevated antibody titers preserved for 8.4 years with 2vHPV and 8 years 
with 4vHPV (Mishra, Pimple, Shastri, 2015).  According to the CDC, clinical trials and current 
research has shown protection from HPV with the vaccine lasts anywhere from 8-10 years with 
no evidence of the vaccine losing efficacy with time (CDC, 2015k).  There is no data related to 
protection over the amount of 10 years because the vaccines were only released 10 years ago in 
2006.  
Long-term antibodies have been credited to plasma cells found in bone marrow which 
constantly produce IgG antibodies (Mishra et al, 2015).  There is evidence of vaccine efficacy 
either with one dose, or with two doses given 6 months apart (Mishra et al, 2015).  Certain 
countries have recently begun to implement vaccination programs using a two-dose series 
instead of a three-dose series, which is why the CDC recently changed the recommendations for 
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younger United States (U.S.) adolescents to receive the HPV series in two doses. Australia’s 
HPV vaccination catch-up program has determined there is still protection from the specific 
strains of HPV with less than three doses, and England anticipates high coverage from the virus 
with a two-dose schedule (Mishra et al, 2015). Overall, one dose of the vaccine alone has been 
predicted to likely be inadequate to stimulate measurable cross-protection, whereas a greater 
amount of cross protection is available following completion of all three doses (Mishra et al, 
2015).   
Although the vaccines are both safe and effective, there are some common side effects.  
These include pain, redness, or swelling in the arm where the vaccine was administered, fever, 
headache, fatigue, nausea, and muscle or joint pain (CDC, 2015e). There is also a risk of fainting 
with any medical procedure or severe (anaphylactic) allergic reactions (CDC, 2015e). The CDC 
(2015e) reports that the most recent 9vHPV vaccine was evaluated in seven studies to determine 
safety. Higher rates of redness and swelling were reported then the previous 4vHPV vaccine, 
with these side effects increasing after administration of subsequent doses of the 9vHPV vaccine 
series (CDC, 2015e).  The CDC released a report in 2014 related to side-effects of the 4vHPV 
vaccine, citing 92% of the side effects were classified as non-serious (CDC, 2015e). Because 
fainting has been known to happen after vaccine administration, the CDC recommends to have 
the patient remain seated and kept under observation for 15 minutes after vaccination (CDC, 
2015e).   
The vaccine is contraindicated for anyone who is severely allergic (e.g. anaphylaxis) to 
any component of the vaccine, severely allergic to yeast, or someone with a moderate to severe 
acute illness (CDC, 2015j; Gardasil, 2015).  Severe latex allergy is a contraindication for the 
bivalent HPV vaccine (Cervarix) because the prefilled syringe cap contains latex (CDC, 2015j).  
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Although there is no proof of adverse pregnancy outcomes, the vaccines are not recommended 
for use during pregnancy, or should be delayed until after pregnancy if the series has already 
been started (CDC, 2015j).   
After a literature review was completed to determine types of lacking inoculation across 
the nation, a need was found for the continued promotion of HPV vaccination education for 
males and females in the age groups of 9-12 and 13-17 (CDC, 2015e). The most recent national 
average statistical data from the CDC has shown slight increases in the number of adolescents 
ages 13-17 vaccinated with either the bivalent or quadrivalent HPV vaccine from year to year 
(CDC, 2015e). Girls with at least one dose of the HPV vaccine had a 3.3% increase from 2013 to 
2014 (56.7% in 2013, 60.0% in 2014), while boys with at least one dose had an 8.1% increase 
(33.6% in 2013, 41.7% in 2014) (CDC, 2015e).   
Several studies have cited a decrease in HPV-related cancer within six years of original 
4vHPV vaccine introduction with results that closely mimic this research (Markowitz et al., 
2016). Markowitz et al. noted in their study that six years after 4vHPV introduction, HPV-related 
cancer prevalence fell from 11.5% to 4.3% with a 34% decrease in prevalence in 14 to 19 year-
olds. There was no statistically significant change in prevalence in cross coverage with other 
uncovered strains (Markowitz et al., 2016). The next section discusses formulation of the 
problem statement which addresses patient population, intervention, comparison intervention, 
outcome, and time frame (PICOT) (Melnyck & Fineout-Overholt, 2015). 
Significance 
HPV is currently the most common STI in the U.S. (CDC, 2015j). With the high 
prevalence of the virus, the CDC predicts nearly all sexually active men and women will acquire 
at least one of over 150 HPV types at one point in their lifetimes (CDC, 2015c). Although HPV 
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vaccine coverage has greatly increased in the U.S., rates remain low in comparison to other 
recommended vaccines (Holman et al, 2014).  
According to Healthy People 2020, the national target percentage for HPV vaccination in 
both males and female adolescents ages 13-15 years old is 80% (HP2020, 2014).  Nationally, 
only a few states have reached a level of 70% or greater (CDC, 2015i).  The state of North 
Dakota (ND), which is where the intervention project takes place, is currently in the 70% or 
greater range for females and 60% or greater range for males (CDC, 2015i).  The Advisory 
Committee on Immunization Practices (ACIP) currently recommends three vaccines (Cervarix, 
Gardasil, Gardasil9) for routine vaccination after researching the efficacy, immunogenicity, and 
safety (CDC, 2015f; CDC, 2014a).  Each of the three vaccines provide immunity for males and 
females (except Cervarix, which is only for females) against specific high-risk HPV types proven 
to be cancer-related (cervical, anogenital, oropharyngeal) as well as protecting against low-risk 
types causing genital warts (CDC, 2014a).  The prevalence of HPV has decreased greatly since 
the first two vaccines (Cervarix and Gardasil) were created in 2006, decreasing from 11.5% to 
5.1% in females ages 14 to 19 when comparing numbers from 2003-2006 and 2007-2010 (KFF, 
2015).  Administration of HPV vaccinations is a strategy that will save thousands of lives (KFF, 
2015).  Through continually educating the public and promoting the use of the HPV vaccines, it 
one can assume that HPV vaccination rates will increase and more people will be prevented from 
acquiring preventable HPV-related cancers. 
The project is significant because the education provides for the continued promotion of 
HPV vaccinations to allow for greater HPV knowledge among North Dakota State University 
(NDSU) students in Fargo, ND.  Students ages 18-26 were targeted for education and vaccine 
promotion within NDSU.  HPV vaccination of young adults between the ages of 16-25 has been 
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proven highly beneficial for several reasons: they are at a higher risk of contracting HPV due to 
the fact that young adult bodies are more biologically susceptible; the lack of STI testing in this 
age group; the hesitancy to talk about sexual activity with their primary care providers; 
limitations in insurance or transportation; and the tendency of having multiple sexual partners 
(Krawczyk et al., 2011; CDC, 2017b).  The problem statement has been formulated to address 
increasing vaccination uptake through the use of education in the university setting. 
Problem Statement 
Clinical Question: Will the provision of HPV education to college students, ages 18-26, increase 
HPV knowledge, vaccine intent, and the number of student HPV vaccinations within six months 
at NDSU? The chosen college setting provides direct access to educate the target population, 
students ages 18-26, who have either already received, or have the potential to receive or 
complete the HPV vaccination series.  
Project Description with Purpose and Objectives 
North Dakota State University (NDSU) in Fargo, ND is where the education intervention 
was completed.  The university’s mission statement is to address the “needs and aspirations of 
people in a changing world by building on our land-grand foundation” (NDSU, 2009).  The core 
values of NDSU include the following values and principles: land-grant, people, scholarship, 
teaching and learning, ethics, culture, and accountability (NDSU, 2009).  Both the mission 
statement and the core values correlate well to the strategic plan and goals of the practice 
improvement project.  The educational sessions met student needs by giving them empowering 
knowledge to make safer sexual choices. 
The most pertinent core values of NDSU to the clinical intervention include people, 
accountability, and teaching and learning.  Improving intellectual and personal development, as 
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well as safety and welfare of students through increasing knowledge about HPV is one of the 
clinical objectives of the clinical intervention.  The desired impact of increasing knowledge to 
reflect safer sexual choices and prevent acquiring the most harmful, cancer-causing HPV types 
positively influenced student’s lives.  It was also anticipated that increasing student 
accountability would allow for improved quality of life through providing the tools and 
knowledge needed to protect themselves and others from the harmful sequelae of HPV. A 
comfortable teaching and learning environment outside of the traditional classroom setting was 
required for the promotion of quality education to NDSU students.  Meetings with two 
organizations (Women’s Activist Organization and Violence Prevention Educators) provided the 
opportunity and setting for the educational sessions to take place.  Attendance at the annual 
spring Sex Positivity Expo also provided the opportunity to interact with NDSU students about 
HPV and HPV vaccine information, as well as invite them to take place in the clinical study.  
Project objectives were established to describe what was anticipated to be achieved by 
the HPV educational program at its conclusion. The objectives identify the target population as 
NDSU students, as well as evaluation of student beliefs, attitudes, and barriers associated with 
the vaccine.   
• Objective One – Determine whether an educational video intervention can 
successfully improve HPV knowledge among NDSU students. 
• Objective Two – Determine whether an educational video intervention can 
successfully improve HPV vaccination intent and vaccine uptake among NDSU 
students. 
• Objective Three – Assess NDSU student beliefs, attitudes, and barriers associated 
with the HPV vaccine.   
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• Objective Four - Provide HPV education to NDSU student participants at the 
annual 2017 spring Sex Positivity Expo. 
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CHAPTER 2. LITERATURE REVIEW AND THEORETICAL FRAMEWORK 
Literature Review 
An extensive systemic literature review and synthesis was performed to determine 
current effectiveness and barriers to HPV vaccine acceptance, school-based interventions, and 
vaccine cost-analysis.  National survey data was also analyzed to determine trends in HPV 
prevalence from when the vaccines were first released in 2006.  The broad amount of literature 
found and number of significant findings on the topic reinforces the need to continue HPV 
education and vaccination promotion in order to reduce morbidity and mortality rates associated 
with HPV (Zimet, 2005).  
Effectiveness and Barriers of Vaccine Acceptance. When considering effectiveness 
and barriers to vaccine acceptance, there are three main categories: parental concerns, clinician 
beliefs/practice styles, and adolescents’ abilities to utilize patterns of health care (Fiks et al., 
2013).  Parents are not only reluctant to vaccinate their adolescent children against STIs, but also 
have concerns about vaccine safety and efficacy (Fiks et al., 2013).  Some clinicians have been 
noted to postpone recommendations due to anticipation of parental objections, doubts about 
safety/efficacy, and knowledge deficits about risk factors, ultimately resulting in missed 
vaccination opportunities (Fiks et al, 2013).  A barrier to adolescents include less frequent 
attendance at well-check visits, ultimately presenting more limitation to provide vaccine 
education and promotion (Fiks et al, 2013).  
 In a study by Fiks and associates (2013), a randomized control trial was performed to 
examine intervention techniques determining which would be the most effective to initiate the 
HPV vaccine series through providing decision support to families, clinicians, or both.  The 
results indicated that a clinician-focused intervention was effective for initiating the series, while 
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the family-focus promoted completion of the series (Fiks et al., 2013).  The results indicate the 
importance of proper provider education to increase initiation rates with the HPV series, reduce 
missed vaccination opportunities, and highlights the need for stricter adherence to providing 
further vaccine education support to families in order to promote series completion (Fiks et al., 
2013).  
 A study completed by Davis et al., (2004) analyzed HPV vaccine parental acceptance of 
male and female adolescents ages 10 to 15. Five hundred and seventy-five parents/guardians 
were asked to complete a 30-question survey in relation to HPV knowledge and vaccine 
acceptance. After the survey, they were asked to read an educational fact sheet and then 
complete another 26-question post survey, reassessing their HPV knowledge.  Parents who were 
opposed to the vaccine typically believed it would promote their children to engage in sexual 
intercourse earlier when compared to those parents who were supportive or undecided about the 
vaccine (Davis et al., 2004).  Twenty-four percent of parents believed it would cause earlier 
sexual intercourse, 9% were supportive, and 6% were undecided (Davis et al., 2004).  Of the 
participants who were initially opposed or not sure about allowing their adolescent to get the 
vaccine, 37% and 65% respectively, supported vaccination post educational intervention (Davis 
et al., 2004).  Therefore, the educational intervention was able to greatly improve parental 
acceptance of the HPV vaccine (Davis et al., 2004).   
 In a systematic review of 55 articles, Holman and associates (2014) also reviewed HPV 
vaccination barriers.  Clinician barriers that were identified included financial concerns, parental 
attitudes, knowledge gaps, insufficient insurance coverage/reimbursement, preference for 
vaccinating older adolescents, and preference for vaccinating girls when compared with boys 
(Holman et al, 2014).  Parental barriers included not receiving a clinician’s recommendation for 
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the vaccine, lack of information, belief that a child is too young, concerns about vaccine adverse 
effects/safety and newness, cost, and access to a clinic that offers the vaccine (Holman et al, 
2014). Underserved population barriers included vaccine knowledge deficit, lack of insurance, 
not receiving a clinician’s recommendation, distrust of health care systems, cultural factors, and 
immigration status (Holman et al, 2014). Specific barriers to males included the assumption of 
no benefit or need to get the HPV vaccination, lack of awareness, not receiving a clinician’s 
recommendation, and cost (Holman et al, 2014). Barriers to completing the three-dose 
vaccination series overall included lack of insurance and medical home, lack of clinician 
recommendation, reduced contact with the medical system, and unawareness or forgetfulness 
(Holman et al, 2014).  
 A study by Walhart (2012) specifically focused on parental barriers identifying three 
central themes to the decision-making process of HPV vaccine administration: parental attitudes, 
beliefs, and barriers. Parental attitudes were brought up which correspond with previous research 
discussed such as knowledge deficit, physician role in vaccine promotion, perceived risk, and 
misunderstanding about the importance of vaccinating both males and females (as opposed to 
just females) (Walhart, 2012). Beliefs included religious, ethnic factors, and normative beliefs 
(Walhart, 2012).  Barriers that were identified included the young age of administration, 
opposition to vaccines in general and three-dose requirement for HPV vaccine, in addition to 
similar concerns found in other studies (Walhart, 2012).  
An interesting finding by Zimet (2005) identified personal acceptability as a barrier to 
vaccination due to the stigma of STIs and acceptance of the vaccine acting as “an admission of 
risky sexual behavior” (Zimet, 2005, S18).  Other empirical research has determined a high level 
of interest in target populations of adolescents and young women, with knowledge of the 
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prevention of cervical cancer as a compelling vaccine feature (Zimet, 2005).  Despite this 
viewpoint, more recent studies have shown that HPV vaccination does not have any impact on 
increasing the amount of sexual activity (Zimet et al., 2013, Smith et al., 2015; Jena et al., 2015; 
Mayhew et al., 2014).  A quasi-experimental study in Canada reviewed health databases of 
128,712 8th and 9th grade girls estimating risk difference and relative risk regarding HPV 
vaccination (Smith et al., 2015). The authors found strong evidence that any concerns of 
promiscuity increasing post HPV vaccination is unwarranted (Smith et al., 2015).  
In 2013, Zimet and colleagues looked further into this topic through a review of 
behavioral science research exploring beliefs and behaviors linked with myths and 
misinformation affecting HPV vaccine uptake, or increased rates of HPV vaccination.  Parental 
fear of their children’s disregard for sexual safety following receipt of the vaccine has been listed 
as a top reason for bypassing the HPV vaccine (Zimet et al., 2013). Contrary to this belief, 
several cross-sectional studies have shown no evidence of this, with one even finding that 
adolescents recognized a need for safer practice with sexual behaviors (Zimet et al., 2013).  
These results may provide assurance to apprehensive parents and providers that there are no 
increased risks associated with the vaccine (Zimet et al., 2013). Other issues brought to light in 
this study are the beliefs that the vaccines are too new, causing parents to doubt the vaccine’s 
safety (Zimet et al., 2013).  Many studies have been conducted on HPV vaccine safety and any 
adverse effects associated with them showing little to no evidence of adverse health effects 
(Zimet et al., 2013). The third major influence on vaccine uptake includes healthcare provider 
recommendation (Zimet et al., 2013).  This has been found to be negatively affected by several 
concerns: safety and efficacy; patient age; time constraints; and fear of alarming parents with the 
discussion of their child’s sexuality (Zimet et al., 2013). 
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School-Based Interventions.  A study to compare the efficacy of HPV interventions was 
completed to evaluate if there were increased HPV knowledge and vaccination intentions in 
college students (Krawczyk et al., 2012).  The compared interventions consisted of written and 
video interventions, and HPV knowledge and vaccination intentions were assessed both before 
and after the interventions (Krawczyk et al., 2012). Participants, including 60 males and 140 
females in universities in Montreal and Quebec, Canada, were randomly assigned to either a 
written, video, or control group (Krawczyk et al., 2012). The written and video interventions 
discussed HPV incidence, transmission, consequences of HPV, and vaccine efficacy and safety.  
The control group discussed information relating to healthy lifestyle choices to prevent cancer.  
The first study objective was to determine if the educational intervention successfully improved 
HPV knowledge.  Both the written and video interventions greatly improved knowledge when 
compared with the control group.  The second study objective was to determine if educational 
interventions improved the intent to vaccinate.  The written and video interventions resulted in 
increased vaccination intentions more significantly when compared to the control group.  The 
third objective was to see if a HPV video had a greater impact with increasing knowledge and 
intent to vaccinate when compared with the same information given to students in a written 
format.  Results indicated that there was no difference between the two interventions when 
measuring increase in knowledge and vaccination intent (Krawcyzk et al., 2012).    
 A cross-sectional, descriptive study was completed by Donadiki et al. (2014) to examine 
reasons for female university student HPV vaccine refusal, and assess beliefs, attitudes, and 
barriers related to the HPV vaccine series.  The study included a sample size of 2007 Greek 
university students ages 18-26, and utilized a self-administered questionnaire incorporating 
Health Belief Model (HBM) directed questions.  The study analyzed both demographic (age, 
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employment status, and relationship status) and independent variables (health/sexual behaviors) 
(Donadiki et al., 2014).  Results of the study indicated that being in a stable relationship was 
more consistent with non-HPV vaccination.  Smokers were shown to be more likely to refuse the 
HPV vaccine, which could also reflect less healthy lifestyle choices in general. Students who had 
never visited a gynecologist had a greater likelihood of not being vaccinated with the HPV 
vaccine.  Results indicated that students who were more likely to refuse the HPV vaccine or be 
non-vaccinated were positive for a lack of information, having a higher number of barriers (cost, 
lack of social security), belief in no benefits to them, and belief that the HPV vaccine were 
neither safe nor effective (Donadiki et al., 2014).  These results have shown to be consistent with 
other studies that have been completed (Donadiki et al., 2014).        
 In an on-going Australian study, Skinner et al. (2015) developed a two-year cluster 
randomized controlled analysis to evaluate how effective strategies would be to promote HPV 
vaccination in the school setting. The study goals were to evaluate vaccination-related 
psychosocial outcomes (knowledge and attitudes, decision-making, and self-efficacy), to reduce 
any fear and anxiety associated with the vaccine, and to improve vaccination uptake.  A school-
based delivery of vaccines is used in Australia, and adolescents are eligible to participate if a 
consent form is signed by their parent (Skinner et al, 2015).  Past research completed in 
Australian schools has shown that “adolescents’ understanding, self-efficacy, and involvement in 
decision-making regarding HPV vaccination are low, and that their fear and anxiety are high” 
(Skinner et al, 2015, p 2). The intervention consisted of three components: adolescent 
intervention, parent/adolescent decision support tool, and logistical strategies.  The adolescent 
intervention involved education given at the school in a lesson, a take-home magazine, an app 
for mobile devices and distraction/relaxation methods to be used before vaccination (Skinner et 
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al, 2015).  The decision support tool was designed for use in the home environment.  Logistical 
strategies included methods of increasing vaccine uptake including mailing vaccination consent 
forms to parents, reminders, non-material incentives (homeroom points), and guidelines for 
nurses and teachers to lessen student anxiety and promote student privacy (such as providing 
distraction techniques) (Skinner et al, 2015).  Internationally there is an interest in the HPV 
vaccination because so many countries are not able to meet vaccination target numbers (Skinner 
et al, 2015). There are no conclusive study results now because the study is currently in progress.  
 A Capstone Project was completed in 2013 by Denise Barry, a Doctor of Nursing 
Practice student, regarding increasing HPV knowledge and vaccine promotion in a school-based 
setting.  The project allowed the student to reach out to adolescents and parents to promote HPV 
education.  Parents were targeted through an informational booth at parent information night, 
providing education about HPV and the vaccine. A 50-minute educational session was presented 
to a ninth-grade health class, with a pre-test and post-test administration.  A handout with HPV 
education was also created and sent home with all the students.  Overall results indicated an 
increase in knowledge about HPV and the HPV vaccine in the adolescent population (Barry, 
2013).  The number of adolescents who intended to get the HPV vaccine in the future was also 
increased (Barry, 2013). A measurement tool was not generated regarding the parental 
population.   
 An educational intervention study aimed at HPV and the HPV vaccine was completed by 
Reiter et al (2011) in a school setting to increase basic HPV knowledge and vaccine uptake.  
One-time intervention sessions were completed in schools to a target audience of parents, 
healthcare staff, and school staff, with self-administered pre-and post-tests used to evaluate 
learning.  An educational PowerPoint presentation was given, covering the topics of HPV 
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prevalence/transmission, associated diseases, vaccine recommendations, dosage schedule, 
vaccine efficacy/safety, and insurance coverage (Reiter et al, 2011).  The pre-and post-surveys 
included self-rated knowledge and multiple-choice items. A handout was provided during the 
education session with similar information. Results indicate low levels of HPV objectivity and 
vaccine knowledge prior to the intervention.  A significant result of the study was over 90% of 
school staff members thought the HPV and HPV vaccine education is important for school 
personnel and that the setting was an appropriate choice in venue to administer the information 
(Reiter et al, 2011).  The study concluded overall the intervention succeeded to greatly increase 
knowledge among influential parties of adolescent females (Reiter et al, 2011).  
 The following figure shows the status of each state’s policy regarding HPV mandates, 
education, and funding.  Twenty-two states currently have some form of HPV policy in place, 
while 29 states have no policies in place (KFF, 2015).  Virginia, DC, and Rhode Island are the 
only three states which currently require the HPV vaccination to attend school (KFF, 2015).    
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Figure 1. State HPV Vaccination Policies (KFF, 2015) 
 A school-based education cluster randomized controlled study by Grandahl et al. (2016) 
was completed to increase HPV vaccination in 18 schools in Sweden.  Each school was placed in 
an intervention or control group, and both male and female students were invited to participate. 
The initial intervention involved a one-hour face-to-face health interview.  Students in the 
control-group received general information, while the intervention-group received information 
guided by the Health Belief Model (HBM).  A baseline questionnaire was completed, with a 
follow-up questionnaire completed after three months.  A handout was also given to students in 
both groups including general facts, transmission information and sequelae, risk factors, 
prevention, locations to receive the vaccine, vaccine facts, and importance for cervical screening 
(Grandahl et al, 2015).  The results indicated the intervention influenced behavior due 
vaccination rates in the intervention group being slightly higher than the control group, and 
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overall the intervention had positive effects about HPV prevention with an increase in HPV 
vaccination rates (Grandahl et al, 2015).      
Cost-Analysis.  A cost-analysis of the newest HPV vaccine, Gardasil 9, in comparison 
with the cost-effectiveness of previous HPV vaccines, was conducted to further justify the need, 
practicality, and sustainability of the proposed project.  The cost of treating HPV and HPV 
associated cancers is well known, and the projected cancer incidence in the US is well studied. 
Assuming the vaccine is available, easily administered, broadly used, and safe and effective, 
potential health benefit outcomes can be projected. Researchers showed through simplified 
statistical models that 9vHPV vaccine strain carries a better financial benefit then 4vHPV 
(Durham et al., 2015; Chesson et al., 2016b).  
Durham and associates (2015) participated in a recent study assessing cost-effectiveness 
of the nonavalent HPV vaccine both at the state level and national level. The newest nonavalent 
vaccine, 9vHPV, was determined to be more cost-effective compared to the bivalent and 
quadrivalent vaccines (Durham et al., 2015).  However, the newest vaccine is also more 
expensive than previous HPV vaccines.  9vHPV is listed at a per-dose cost of $126, which is $13 
more expensive than Gardasil and $18 more expensive than Cervarix (Durham et al., 2015). 
Using the 9vHPV was found to produce better health benefits while producing the same or lower 
societal costs, and predicted expansions of coverage prevented up to 66% more cervical cancer 
and related deaths when states with lowest coverage were compared with states of high coverage 
(Durham et al., 2015). 
Chesson and associates (2016a) developed a study determining the impact and cost-
effectiveness of U.S. females vaccinated with 9vHPV after they had previously been vaccinated 
with 4vHPV.  The overall results of the study conclude that, with the high degree of variability 
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found in results, findings are not able to fully support the claim that additional 9vHPV 
vaccination is cost-effective.  At the same time, the results did not rule out the possibility of 
additional vaccination having a high amount of cost-effectiveness (Chesson et al., 2016a).  A 
similar study by Chesson and associates (2016b) evaluated cost effectiveness and projected 
quality-adjusted life years (QALYs) of 4vHPV compared to 9vHPV.  Results determined   
vaccination of both sexes with 4vHPV strains reduced projected cancer rates by 53.4%. If cross 
protection was assumed, projected cancer rates increased to 63%.  9vHPV vaccination increased 
overall protection to 65.3% for both sexes, an 11% increase.  QALY gained and cost projected 
analysis with 9vHPV for both sexes saved about $386 million dollars and resulted in a gain of 
147,000 QALYs. Most of the benefit incurred form providing vaccinations to females (Chesson 
et al., 2016b).  Sensitivity analysis of providing 9vHPV to both genders in comparison to 4vHPV 
resulted in costs under $10,000 per QALY in three projected vaccination scenarios over 100 
years.  The result implied actual cost saving will take considerable time to occur. The cost of 
treating HPV and HPV associated cancers is well known, and the projected cancer incidence in 
the US is well studied. Assuming the vaccine is available, easily administered, broadly used, and 
safe and effective, potential health benefit outcomes can be projected. Researchers showed 
through their simplified statistical model that 9vHPV vaccine strain carries a better financial 
benefit then 4vHPV (Chesson et al., 2016b). 
National Survey Data.  There has been an overall reduction in HPV prevalence since the 
vaccine was first introduced in 2006 (Markowitz, 2013).  Data measurement was completed from 
the prevaccine era (2003-2006) and the vaccine era (2007-2010) through analysis of National 
Health and Nutrition Examination Surveys (Markowitz, 2013).  Cervicovaginal swab samples 
were taken from women ages 14-59 years old, with 4150 total samples in 2003-2006, and 4253 
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total samples in 2007-2010 (Markowitz, 2013).  In females ages 14-19, high-risk HPV types 
decreased from 11.5% (2003-2006) to 5.1% in 2007-2010 (a drop of 56%) (Markowitz, 2013).  
The prevalence did not decrease significantly with other age groups within the two time periods.  
These numbers show a substantial decrease in HPV prevalence within four years of introduction 
of the HPV vaccine. 
A similar study by Markowitz et al. (2016) was done to determine the comparison 
between prevaccine (2003-2006) and an extended vaccine era (2009-2012) through analyzing 
data from cross-sectional surveys.  Cervicovaginal specimens were examined from females ages 
14-34 years old, and prevalence of 4vHPV types and other HPV types were compared. Overall, 
within six years of the release of the HPV vaccine, a 64% decrease was seen in 4vHPV type 
prevalence (in females 14-19 years old), and 34% decrease was seen in 20 to 24-year-old females 
(Markowitz et al, 2016).  
Health Promotion Model 
The Health Promotion Model (HPM) is a nursing theory developed by Nola Pender in 
1982 and later revised in 1996 (Pender, Murdaugh, & Parsons, 2011).  The purpose of the theory 
is to help nurses understand determinants of health behavior to promote the development of 
healthy lifestyles (Pender et al., 2011).  The theoretical foundation of the HPM are based on the 
Expectancy Value Theory, where actions are taken to achieve goals that achieve favorable 
outcomes, and the Social Cognitive Theory, which examines the interactions of thoughts, 
behavior, and the environment (Pender et al., 2011).   
Key concepts utilized in the HPM are person, environment, nursing, health, and illness. 
Together these concepts work together to form the basis of the HPM.  There are eight beliefs 
which are the main focal points of the HPM (Pender et al., 2011).  These beliefs are assessed by 
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the nurse and aid in helping the nurse change behaviors to influence healthier lifestyles.  The 
beliefs focused on by the HPM are the following: 
1. Perceived benefits of action 
2. Perceived barriers to action 
3. Perceived self-efficacy 
4. Activity-related affect 
5. Interpersonal influences 
6. Situational influences 
7. Commitment to the plan of action 
8. Competing demands and preferences 
There are two other factors the HPM takes into consideration which influence each 
individual’s lifestyle. Unique characteristics and experiences such as past health behaviors, and 
personal factors such as age, personality, race/ethnicity, and socioeconomic status (Pender et al., 
2011). The other factor considered is health promoting behavior that determines a desired health 
outcome or behavioral end point, and how individuals are prepared to take action to achieve the 
desired outcome (Pender et al., 2011).  The following seven assumptions are also made which 
reflect both nursing and behavioral science: 
1. Individuals strive to create living conditions to express unique health potential. 
2. Each person has the ability to assess their abilities and self-reflection. 
3. Positive outcomes are desired and a balance needs to be found between change 
and stability. 
4. Self-regulation of behavior is preferred. 
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5. All individuals interact with the environment in a complex way, both 
transforming themselves as well as the environment over time.  
6. Health professionals influence individuals throughout the lifespan. 
7. Self-initiation is required for behavior change.  
The HPM is compatible with the clinical project question. Understanding determinants of 
health for both individuals and the target population was helpful for the nurse to promote 
individuals in making healthier sexual lifestyle choices.  Being aware of beliefs which influence 
the decision to make positive or negative health choices allow the nurse to have a greater 
awareness of all contributing factors which influence both past health choices as well as future 
health outcomes.      
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Figure 2. Health Promotion Model. (Pender et al., 2011) 
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CHAPTER 3. PROJECT DESIGN 
 
Needs Assessment 
The need exists to improve HPV vaccination rates among young adults in North Dakota.  
North Dakota statistical data, while close to national average percentages in all levels of the HPV 
vaccination completion series for adolescents ages 13-17, could be improved.  The estimated 
vaccination coverage with one or more doses of HPV vaccine in females in North Dakota is 
60.9% when compared with the national average (NA) of 60.0%, and males at 37.6% when 
compared with NA of 41.7% (CDC, 2015h). Estimated vaccination coverage with two or more 
doses in ND females is 48.7% when compared with the NA at 50.3%, and males at 32.1% in 
comparison with the NA at 31.4% (CDC, 2015h). The estimated vaccination coverage with three 
or more doses in females is 41.7% when compared to the NA of 39.7%, and males at 25.3% in 
comparison with the NA at 21.6% (CDC, 2015h).  Estimated vaccination coverage of three dose 
HPV vaccine series completion in ND females is 75.8% when compared with the NA at 69.3%, 
and males at 71.7% when compared to the NA of 57.8% (CDC, 2015h). According to Healthy 
People 2020 (HP2020), the national target percentage for HPV vaccination in both males and 
female adolescents ages 13-15 years old is 80% (HP2020, 2014).  The baseline to receive at least 
3 doses of the HPV vaccine in 2012 for females was 28.1% and 6.9% in males.  North Dakota 
females ages 13-15 years’ old who have completed three or more doses of HPV was listed at 
41.4%, and males at 18.1% when compared to the HP2020 goal of 80% (CDC, 2015h).  
The next figure describes the most recent information taken from the CDC regarding 
2016 percentages receiving at least one or more doses of HPV vaccine.  These numbers show a 
great improvement from the baseline percentages in 2012.  However, there is still a significant 
amount of work to do to get to the HP2020 80% target.   
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Figure 3. 2016 Nationwide HPV Vaccine Information (CDC, 2015i) 
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Project Implementation 
The HPV vaccination education intervention plan utilized the Health Promotion Model 
(HPM) to assist the nurse in understanding individual determinants of health to promote 
knowledge about HPV and the importance of receiving the vaccine series. The HPM emphasizes 
the importance of the promotion of healthier lifestyles choices, which fits in with the clinical 
project aim of giving students the knowledge they need to protect themselves from sexually 
acquiring harmful strains of HPV (Pender et al., 2011).  Individual characteristics and 
experiences, behavior-specific cognitions and affect, and health promoting behavior are all key 
parts of the HPM which helped to facilitate nurse promotion of learning for NDSU students 
(Pender et al., 2011).  Survey data addressing student health data and attitudes/beliefs was 
collected to better understand and facilitate student health promotion. 
The project has been designed with the following study inclusion criteria:  
1. Currently a NDSU student in the age range of 18-26. 
2. Able to read and understand English independently. 
3. Physically and cognitively able of completing a written/online survey as identified 
by school or administrative personnel. 
4. Must be present on the day of education (applies to organization meetings only). 
The first step to begin project intervention implementation involved the development of 
the main educational video, the pre/post survey, the 3 and 6-month reassessment surveys, and a 
supplemental VoiceThread PowerPoint with additional HPV vaccine information.  An 
educational video presentation was chosen that would best appeal to the target population. The 
video was developed by a team of Canadian professional associates, led by Dr. Mike Evans, a 
physician with many years of experience.  The supplemental PowerPoint was developed by the 
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nurse researcher to reflect basic educational information related to HPV and the vaccine 
(including prevalence/transmission), long-term negative health implications (cancers), vaccine 
recommendations, dosage schedule, vaccine efficacy/safety, and student resources. Pre-and post-
surveys were developed using a combination of research tools and the Health Promotion Model 
(HPM) (Denise Barry, 2013; Donadiki et al., 2014; Pender et al., 2011).  Permission was granted 
for usage of both tools with modifications, as well as the HPM, which primarily addressed 
questions assessing student beliefs, attitudes, and barriers (Pender et al., 2011).      
Project implementation involved two components.  The main component of the 
intervention plan took place during either one weekly or biweekly meeting of two NDSU 
organizations: Women’s Activist Organization (WAO) and Violence Protection Educators 
(VPE).  Students began by taking an online Qualtrics pre-survey to establish a baseline about 
HPV knowledge, HPV vaccine knowledge, beliefs, attitudes, barriers, current HPV vaccine 
status (vaccinated or not vaccinated), and intent to receive the vaccine series if they have not.  
Next, a 10-minute educational you-tube video was watched, entitled “Should You Get the HPV 
Vaccine?” Student questions were answered after viewing the video.  Two registered nurse 
representatives from Student Health Services were present during the education sessions to assist 
in answering questions students had about how much the vaccine costs to receive, scheduling a 
time to receive the vaccine series, and other various questions students had about receiving the 
vaccine series through Student Health Services at the Wellness Center.  Last, an online Qualtrics 
post-survey was administered to assess if baseline knowledge, beliefs, attitudes, barriers, or 
overall student intent to receive the vaccine had improved after receiving the education.  Student 
email addresses were collected at the end of each online survey to send out three and six-month 
follow-up surveys to assess if students either started or completed the HPV vaccine series since 
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taking part in the clinical intervention.  An educational CDC handout about HPV was given to 
students at the end of the intervention, as well as a link to the supplemental online VoiceThread 
PowerPoint, and Student Health Service cards with contact information for questions or 
scheduling a time to start or finish the HPV vaccine series.       
The second component of the intervention involved participating in the annual spring Sex 
Positivity Expo (SPE), which took place on the second level of Memorial Union in the Plains 
Room from 5-8 pm on April 4, 2017.  The same two Student Health Services registered nurse 
representatives were present during this event to assist in answering questions students had about 
receiving the vaccine series through NDSU. A booth was reserved where the nurse researcher 
and Student Health Services representatives were able to speak with participants about HPV and 
the importance of the vaccine.  Each participant was asked if they would like to participate in the 
clinical project and had the choice whether or not to leave their email address.  Contact was 
made with a total of 52 students at the event.  A total of 14 online pre-and post-surveys were 
started by SPE participants, and eight were completed.   
Timeline.  The timeline for project implementation was enacted as follows: 
1. September 2016: Proposal meeting. 
2. November – December: Reached out to potential organizations at NDSU to whom 
to provide the educational intervention. 
3. March 2017: Request for project approval submitted and granted by NDSU’s 
Institutional Review Board (IRB).  
4. April 2017: Implementation of the Practice Improvement Project at two selected 
NDSU organizations and provision of participant education at the annual Sex 
Positivity Expo. 
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5. July 2017: 3-month reassessment Qualtrics surveys emailed to students. 
6. October 2017: 6-month reassessment Qualtrics surveys emailed to students.  
7. October 2017: Started final analysis of collected data.  
NDSU IRB Approval  
 Documentation was compiled and submitted to NDSU’s Institutional Review Board 
(IRB) for review in compliance with human subject’s protection and NDSU policies.  Approval 
was granted on March 29, 2017 for Protocol number PH17165 (Appendix C).   The approval 
period was listed as 3/29/2017 through 3/28/2018.  The review type was considered to be 
expedited category number six and seven.   
Data Collection 
Permission to use assessment survey tools (with modifications) was granted by researcher 
Denise Corrigan, previously Denise Barry, and Elizabeth Donadiki (Appendix B).  Permission 
was also granted by Nola Pender for the application of the Health Promotion Model (Appendix 
B).  Analysis of initial survey results involved comparison of pre-and post-survey answers. The 
pre/post survey assessed demographic information (gender, age), knowledge related to a general 
understanding about HPV, modes of transmission, who should receive the vaccine, current HPV 
vaccination status of the student, intent to vaccinate, prior indications of personal health, and 
beliefs, attitudes, and barriers (Appendix D, E) (Barry, 2013; Donadiki et al., 2014, Pender et al., 
2011).  Survey questions were asked in the following formats: true/yes and false/no, 
agree/disagree, and select all that apply (Barry, 2013).  
 The main bulk of data was collected in the form of pre-and post-online surveys.  Seven of 
the pre-and post-surveys were from participants at the Sex Positivity Expo who completed the 
surveys outside of the classroom setting.  The educational video was embedded into the survey 
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so that these participants were able to take the pre-survey first, watch the video in the same 
survey, and then take the post survey.  Skewing of data in these surveys was prevented because 
these participants were not given any HPV education counseling during the expo.  Twenty-five 
of the surveys were completed at the time of the educational training sessions during the two 
NDSU organization meetings on campus. Three and six-month follow-up surveys were emailed 
to those participants who consented to receive them. Of the twenty-five participants that gave 
consent for this, seven students responded to each of the three and six-month follow-up surveys.  
The pre-and post-surveys measure quantitative and qualitative data collected through 
online Qualtrics surveys. The post-survey was not identical to the pre-survey because it does not 
contain a few of the belief, attitude, and barrier questions which were repetitive for students to 
answer and intended to provide better understanding of the target population. Survey results were 
acquired anonymously through an “anonymize response” setting on the Qualtrics survey. 
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CHAPTER 4. EVALUATION 
 Each of the four practice improvement project objectives have specific evaluation criteria 
in place to determine if they were successfully met at the conclusion of the project.  There are 
three possible outcomes each objective may be labeled with, including met, partially met, or 
unmet. If the outcome is met, it means that objective was successful. If partially met, it means at 
least a portion of the objective was successful.  If unmet, the objective was not successful.  The 
objectives are listed again as follows: 
• Practice Improvement Objective One – Determine whether an educational video 
intervention can successfully improve HPV knowledge among NDSU students. 
• Practice Improvement Objective Two – Determine whether an educational video 
intervention can successfully improve HPV vaccination intent and vaccine uptake among 
NDSU students. 
• Practice Improvement Objective Three – Assess NDSU student beliefs, attitudes, and 
barriers associated with the HPV vaccine.  
• Practice Improvement Project Objective Four: Provide HPV education to NDSU student 
participants at the annual spring Sex Positivity Expo. 
The first, second, and third objectives were measured by data collected from NDSU 
participants who complete pre-and post-surveys (Appendix D, E).  The expectation for the first 
objective is to have a noticeable increase in knowledge after students watch the educational 
video.  The second objective measured if students who are not already fully vaccinated with the 
HPV vaccine had a favorable response regarding vaccine intent.  The second objective also 
mentions vaccine uptake, which was evaluated through student response to the three and six-
month follow-up surveys.  The third objective examining student beliefs, attitudes, and barriers 
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associated with the HPV vaccine was measured by whether or not there was an increase in 
favorable responses when comparing the pre-and post-surveys.   
Measurement of the fourth objective is determined by how many students stop at the Sex 
Positivity Expo booth for education.  Students who approached the booth were first asked if they 
would like to participate in the project through providing their emails to take the online Qualtrics 
pre-and post- surveys.  This was done to avoid the skewing of any online survey data.  If they 
preferred not to take the survey, they were asked if they had any knowledge about HPV, if they 
had been vaccinated with the vaccine series, or if they had any questions related to HPV or the 
vaccine series.  Appropriate education was given at that time in response to student questions.  
Educational CDC handouts were available to give to students, as well as Student Health Service 
business cards for them to call with any questions or to schedule a time to receive the HPV 
vaccine series.  
A logic model was developed to serve as a tool for evaluation of the practice improvement 
project to organize project information concisely and strategically (Pell Institute, 2016).   
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Table 2 
Logic Model 
Resources/Inputs Activities Outputs Outcomes Impact 
Emily Hegg (NDSU 
Health & Wellness 
Promotion 
Coordinator) 
 
Organization 
presidents: 
Oliva Oland (WAO) 
Kelsey Keimig(VPE) 
 
Graduate Committee 
Members 
 
 
 
 
Pre-test 
 
Educational video 
PowerPoint 
presentation 
 
CDC Educational 
handout 
 
Post-test 
 
Online Qualtrics 
reassessment 
survey 
Collected pre-tests 
 
Collected post-
tests 
 
Collected 
reassessment 
surveys 
 
Participant level: 
Freshman-Senior 
college students  
 
1. Determine 
whether 
educational video 
interventions can 
successfully 
improve HPV 
knowledge among 
NDSU students. 
2. Determine 
whether 
educational video 
interventions can 
successfully 
improve HPV 
vaccination intent 
and vaccine 
uptake among 
NDSU students. 
3. Assess NDSU 
student beliefs, 
attitudes, and 
barriers associated 
with the HPV 
vaccine.   
4. Provide HPV 
education to 
NDSU student 
participants at the 
annual spring Sex 
Positivity Expo. 
Improved vaccination 
intent and increased 
HPV knowledge for 
NDSU students. 
 
Determine student 
beliefs, attitudes, and 
barriers to the HPV 
vaccine.  
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CHAPTER 5. RESULTS 
 
Sample Population 
 The HPV education was provided to two different factions of NDSU college students 
ages 18-26.  The first group consisted of participants at the Sex Positivity Expo (SPE), where a 
booth was set up for students to stop by and ask questions and be offered the chance to 
participate in the online survey.  The second group consisted of two NDSU student organizations 
(WAO and VPE).  Both males and females were encouraged to participate in the online surveys, 
although there were significantly more females than males (26:4).  The age groups were more 
evenly divided into groups of 18-21 (N=14) and 22-26 (N=16).   
Quantitative Data Results 
 The SPE took place on April 4, 2017 in the Plains Room of the Memorial Union, and 
education or survey involvement was available to all NDSU student attendees.  The WAO 
meeting took place on April 5, 2017 in the Rose Room in Memorial Union, and the VPE meeting 
took place on April 11, 2017 in a classroom on the third floor of the Family Life Center.  During 
the SPE, a total of 55 students stopped by the HPV education booth and either visited about what 
questions they had, or were emailed a link to participate in the pre-and post-survey.  A total of 14 
online pre-and post-surveys were started by SPE participants, and eight were completed.  A total 
of 11 surveys were started by WAO participants, and nine were completed.  A total of nine 
surveys were started by VPE participants, and eight were completed.   
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Figure 4. Group Participation 
 
 
 
Figure 5. Cohort Analysis 
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Figure 6. Student Health Data 
 
 A total of 30 students completed either all or part of the pre-and post-surveys.  Health 
data was collected about each student in order to determine overall health information and to 
establish how active students are in maintaining healthy lifestyle habits.  General health 
information such as health insurance status, yearly/sports physicals, smoking status, 
contraceptive use and gynecologist visits were collected. Sexual health information such as 
relationship status, sexual activity, condom use, resources for questions, and HPV vaccination 
starting/completion rates were collected (Appendix D).  
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Have you completed a yearly physical or sports physical
this year?
Have you completed at least one of the HPV vaccine
series of 3 shots?
Have you completed the entire HPV vaccine series?
I have someone I can talk to (parent, nurse, doctor,
friend, teacher) about my questions and concerns…
I make sure to use a condom during any sexual activity.
I have been diagnosed with a sexually transmitted
infection before.
I have had previous oral, anal, or vaginal sexual
experience.
I am currently in a stable relationship.
I have visited a gynecologist in the past.
I currently use oral contraceptives.
 I am currently a smoker.
I currently have health insurance coverage.
Student Health Data
True/Yes False/No Unsure
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Pre-and post-survey questions were collected assessing student HPV knowledge. 
Knowledge questions were designed to assess basic HPV information in the pre-survey such as 
prevalence, sequelae, transmission, vaccine information, and belief of self-risk.  They were also 
designed to assess the educational component of the study to determine if there was an increase 
in learning in the post-survey after viewing the educational video. Answers to the true and false 
questions were all “true”, and answers to the other two questions have been highlighted in the 
following table. Five student participants did not answer questions in the post-test portion, so 
these student’s responses were taken out of pre-test data in the following chart to allow for better 
data comparison. 
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Table 3 
Education Questions 
Variable Pre-test Post-test 
 True False Unsure True False Unsure 
I believe I could be at risk for 
getting HPV. 
 
 N= 9       N= 10       N= 2  
 
N=10         N=10        N=1 
The highest rates of new genital 
HPV infections occur in young 
adults in their late teens and 
early 20s. 
 
 
 N= 22        N= 2         N= 1 
 
 
N=22         N=1          N=2 
If I am infected with HPV, I 
could get genital warts and/or 
cancer. 
 
 N= 21        N= 2         N= 2 
 
N=24         N=1           N=0 
It is estimated that nearly 100% 
of sexually active men and 
women will become infected 
with HPV at some point in their 
lifetime.  
 
 
 N= 6          N=14        N= 5 
 
 
N=22         N=3          N=0 
Human papillomavirus (HPV) 
is the most common sexually 
transmitted infection in the 
United States.  
 
 
 N= 15         N= 6        N= 4 
 
 
N=21         N=3           N=1 
 M F Both M F Both 
Who should receive the HPV 
vaccine? 
A. Females 
B. Males 
C. Both 
      
 
  N=0           N=1         N=24 
  
 
  N=0          N=1         N=24 
 D E F D E F 
How is HPV transmitted? 
A. Skin-to-skin contact 
B. Contact with infected blood 
C. An infected person coughs 
or sneezes on another person. 
D. Vaginal, oral, or anal sex 
E. A&D 
F. B&C 
 
 
 
 
N=12       N =11        N=2 
 
 
 
 
   N=6         N=18         N=1 
 
    
Belief, barrier, and attitude questions were designed to assess student beliefs and attitudes 
towards the HPV vaccine (and all vaccines in general), and barriers (such as vaccine cost or 
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needing additional information).  Certain pre-and post-survey answers consisted of “True/Yes” 
or “False/No”, or “Absolutely Agree”, “Agree”, “Neutral”, “Disagree”, or “Absolutely 
Disagree”. Statistical analysis was evaluated on all pre-and posttest answers. It was determined 
that, due to the small sample size, confidence intervals and p-values would not be included in  
study results due to a lack of statistical significance.  Descriptive statistics was decided to be of 
more value to describe overall results. Knowledge/education and belief/barrier/attitude results of 
pre-and post-responses can be seen in the below graphs.  
 
Figure 7. Belief, Barrier, Attitude Increase Questions 
5=Absolutely Agree, 4=Agree, 3=Neutral, 2=Disagree, 1=Absolutely Disagree 
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vaccine is safe.
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protected from cervical cancer.
I believe that if I receive the HPV vaccine, I will
protected against the most cancer-causing strains of…
I have the knowledge and skills to make safe sexual
choices.
I am motivated to maintain a healthy lifestyle.
I intend to receive the HPV vaccination series in the
future.
Belief, Barrier, Attitude Questions Intended to Increase 
Mean Results
Pre Post
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Figure 8. Belief, Barrier, Attitude Decrease Questions 
5=Absolutely Agree, 4=Agree, 3=Neutral, 2=Disagree, 1=Absolutely Disagree 
 
 Questions were also designed to determine significance of implications for future 
practice. Question answers consisted of “True/Yes” or “False/No”, or “Absolutely Agree”, 
“Agree”, “Neutral”, “Disagree”, or “Absolutely Disagree”.  The last question in the graph (Do 
you feel this education has motivated you to engage in safer sexual practices in the future) 
consisted of a “Yes” or “No” answer.  
 
Figure 9. Implications for Future Practice  
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3-6 Month Reassessment Surveys 
 Reassessment surveys were sent out to participating students at three and six months after 
the initial education sessions were provided, to which seven students responded to each. 
Questions asked in the follow-up surveys assessed the following: if the education sessions made 
students more likely to receive the vaccine; if students were vaccinated with the HPV vaccine 
before the education was given; if students made an appointment with Student Health Services or 
their health care providers to begin the HPV vaccine series or if they received any HPV 
vaccinations since participating in the education; or if students plan on receiving the vaccine in 
the future.  Questions also addressed whether students were already fully vaccinated at the time 
of education, if they are not interested in receiving the vaccine, or if they would like more 
information about the HPV vaccine.  If students indicated on the survey that they wanted more 
information, they were directed to the CDC website addressing HPV vaccine information.  
 The results of the three and six-month surveys were identical to each other in all question 
responses. Results revealed four of seven respondents were more likely to receive the HPV 
vaccine. Six of seven students were vaccinated with at least part of the HPV vaccine series, and 
one student was not.  Four students stated they had not made an appointment to receive the HPV 
vaccine, and one student was unsure.  Five students answered they had not received any HPV 
vaccination since the education session, and five had indicated they were already fully 
vaccinated.  Two students indicated they do intend to receive the vaccine in the future. Three 
students disagreed they were not interested in receiving the HPV vaccine, and three students 
indicated they would like more information about the HPV vaccine.  
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Figure 10. Reassessment Survey Responses  
 
Qualitative Data Results 
 Qualitative data was also collected.  An open-ended question at the end of the post-
survey allowed students to type in a response about why they did or did not believe in the HPV 
vaccine. The follow responses were recorded: 
• Doesn’t sound like there are many downsides. 
• It can save you and others from getting cancer. 
• I received it when I was 15 and I think it’s a good thing to prevent rather than to cure. 
• I want to prevent any potential future problems. 
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• I believe that health care providers work to provide the public with safe vaccinations that 
help keep our population healthy. 
• It’s a vaccine. That prevents cancer. It’s so important. 
• Protection against cancer, duh! 
• Vaccines save lives! 
Program Evaluation 
 Program success was evaluated by going through each objective to decide if they were 
“met”, “partially met”, or “unmet”. The first objective was to determine whether an educational 
video intervention was able to successfully improve HPV knowledge among NDSU students. 
There was a clear increase in a majority of post-survey mean response in education/knowledge 
questions, as seen previously in table 3, indicating this objective was met. Facilitating factors 
that made the objective achievable include the educational video used to enhance learning, and 
the assessment tool (pre-and post-surveys) to assess knowledge.  A barrier to this objective 
includes the drop-out rates of student responses in the post-survey.   
 The second objective was to determine whether an educational video intervention was 
able to successfully improve HPV vaccination intent and uptake among NDSU students.  Intent 
to vaccinate increased in mean numbers from the pre-survey (3.53) to the post-survey (4.1), and 
two students in the reassessment surveys indicated they planned on receiving it in the future 
(Figure 7, 9).   Vaccine uptake was addressed in the reassessment surveys.  When asked whether 
or not any students had made an appointment with Student Health Services or their primary care 
providers to receive the HPV vaccine, four indicated they had not, and one student was unsure 
(Figure 10). When asked whether or not students had received at least one dose of the HPV 
vaccine since the educational session, five students indicated they had not (Figure 10).  
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Information from the pre-survey indicated 21 (70%) students had been fully vaccinated with the 
HPV vaccine series, and 22 students had at received at least one part of the HPV vaccine series.   
However, four students indicated the education they received earlier in the year did make them 
more likely to receive the HPV vaccine (Figure 10).  From this data, it appears that vaccine 
intent was positively impacted, but evidence of vaccine uptake was not achieved.  Therefore, this 
objective is partially met. Facilitating factors that made the objective achievable include the 
educational video used to enhance learning, and the assessment tool (pre-and post-surveys) to 
assess knowledge.  A barrier to this objective included the number of students that were already 
vaccinated with all or part of the HPV vaccine series.   
 The third objective was to assess NDSU student beliefs, attitudes, and barriers associated 
with the HPV vaccine.  These were assessed in pre-and post-surveys.  There was an overall 
increase in majority of mean post-survey results in the belief, attitude, and barrier questions, 
indicating a positive response to education, and giving this objective a label of “met” (Figure 
10). Facilitating factors that made the objective achievable include the educational video used to 
enhance learning, and the assessment tool (pre-and post-surveys) to assess knowledge. A barrier 
to this objective includes the drop-out rates of student responses in the post-survey.   
 The fourth objective was to provide HPV education to NDSU students at the annual 2017 
spring Sex Positivity Expo.  A total of 55 students stopped by the booth set up at this event, and 
either chose to participate in the pre-and post-survey or simply to ask questions and receive 
education at that time.  In describing group participation previously (Figure 4), one can see the 
participants from this event made up the largest group which completed the pre-and post-
surveys. Due to the sizeable number of students who stopped by the booth and participated in the 
surveys, this objective is met.  Facilitating factors that made the objective achievable include the 
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annual meeting of the Sex Positivity Expo and communication with the Woman’s Activist 
Organization’s president to set up a booth at the event. A barrier to this objective includes 
students who declined HPV education/discussion at the event.   
The educational session was also evaluated by a question at the end of the post-survey 
asking students how reliable they found the information presented to them in the video.  
Question responses included “Very Reliable”, “Reliable”, “Slightly Reliable”, and “Not at All 
Reliable”.  Eighteen students (60%) rated the video information as “Very Reliable”, six (20%) 
rated it as “Reliable”, and one (3%) rated it as “Slightly Reliable”.  Overall, this was a good 
response to the education, as the majority of students gave it the highest possible rating.  
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CHAPTER 6. DISCUSSION AND RECOMMENDATIONS 
 Current research data recommends providing health education to college students in order 
to increase uptake of the HPV vaccine series (Thompson et al., 2017).  Higher education 
institutions such as colleges and universities are ideal places to focus on catch-up HPV 
vaccination (18-26 years) because a greater focus is placed on preventive health education and 
the development of greater responsibility when making personal decisions (Thompson et al., 
2017). There is also better availability and access for students in regard to campus health care 
services (Thompson et al., 2017). Lower knowledge levels have been connected with both high 
and low acceptability, meaning education and knowledge don’t always positively affect vaccine 
uptake (Carnegie et al., 2017).  Regardless, knowledge and education are important in order for 
patients to be able to make an informed decision about whether or not to be vaccinated (Carnegie 
et al., 2017).  
A positive response was received from NDSU student participants to the HPV education 
sessions.  Although over half of students had received part or all the of the vaccine series, many 
didn’t know what it protected them against.  Several students had questions about risk factors, 
transmission, and sequelae which were addressed in discussion at the end of each education 
session. Discussions were constructive and able to allow students to think in-depth about 
protecting their sexual health.  This is beneficial particularly during college years where sexual 
experimentation may be at an all-time high (Garcia, 2013).   
 Of the 30 students who participated in the pre-and post-surveys, 22 students (73.33%) 
had completed at least one of the HPV vaccine series of three shots, and 21 students (70.0%) had 
completed the entire HPV vaccines series. Four students indicated they were unsure if they had 
started/completed the series.  Although over half of student participants had completed the 
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vaccine series, HPV education was still beneficial to them for a few important reasons.  The 
education allows students to focus on sexual health and prevention as a primary means of 
stopping the acquisition of HPV (which can also be translated to prevention for other sexually 
transmitted infection), allowing them to think about their own sexual habits and whether they are 
considered to be high risk.  Another benefit of the education is, as potential future parents of 
children who will hopefully receive the HPV vaccine, these participants will know how 
important it is for those children to be vaccinated in order to be protected from HPV-related 
cancers.  The goal was for the other 30 percent of students who had not received the vaccine, or 
who were unsure if they had, to develop their interest in receiving the vaccine and hopefully to 
actually receive it before being exposed to any high-risk types of HPV which may lead to cancer.  
Half of this goal was achieved, which will be discussed in later in the chapter.   
 The following paragraphs discuss different segments of results as seen in the previous 
chapter.  A large amount of data was collected in order to make correlations between different 
variables.  The first section to be discussed is student health data.          
Student Health Data 
Student health data was collected in order to determine how motivated students were to 
take an active role in their healthcare. It was interesting to note both pre-and post-survey 
approximately 50% of students believed they could be at risk for getting HPV.  Correlating with 
this, only about 40% of students used a condom with sexual activity, while 48% did not.  This 
places the group who doesn’t use condoms at a higher risk for acquiring HPV (or other 
consequences), although transmission can also occur with nonpenetrative sexual activity (CDC, 
2015j).  Only about 40% of student participants used contraceptives. Twenty-four students (80%) 
indicated they had previous oral, anal, or vaginal sexual experience, while only 6 students (20%) 
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had been previously diagnosed with a sexually transmitted infection (STI).  This is a smaller 
number of students than was expected to have been diagnosed with a previous STI based on how 
many had sexual experience, as research indicates HPV infection usually occurs shortly after the 
onset of sexual activity (CDC, 2015j).  However, other factors such as how many partners, etc., 
had not been specified.  Ten students (33.33%) indicated they were in a stable relationship, while 
20 students (66.67%) indicated they were not.  While a majority of students were not in a stable 
relationship, a majority also indicated some type of sexual experience in the past.  This data 
substantiates evidence that a majority of adults in their late teens and early 20’s is when the 
highest rates of new genital HPV infections occur (CDC, 2015j). 
 Almost 90% of students had someone they could talk to about questions associated with 
HPV or the vaccine.  This can be associated with meaning they have someone to talk to about 
other health concerns as well (such as a parent, friend, teacher, or health care professional), 
which shows many students have a good support system. One hundred percent of students had 
health coverage, although the question did not specify what type of health coverage they had 
(private, Medicaid, etc.). It is assumed that many students were likely still covered by a parent’s 
health insurance as the age limit is currently 26.  The insurance topic came up during both group 
discussions when students asked how insurance coverage would work to pay for the vaccination 
series on campus.  
Education Questions 
An overall increase in knowledge between pre-and post-surveys in a majority of 
knowledge-based questions was noted.  The education question with the biggest change in pre-
and post-survey percentage was the question asking if it was true or false that nearly 100% of 
sexually active men and women will become infected with HPV at some point in their lifetime. 
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Eight (26.67%) students answered correctly (true) in the pre-survey, and 22 (88.0%) students 
answered correctly in the post-survey.  As noted during the discussion at the end of the 
educational session, this was one of the more shocking education components for students, as 
many couldn’t believe the high rate of prevalency this virus has in the community.  One student 
asked, “If HPV is so common, why should we take any extra precautions to prevent acquiring it 
if we are almost 100% guaranteed to get it?”  This was a good opportunity for some education to 
be provided about the importance of receiving the catch-up HPV vaccine series to better protect 
them.  It was explained that with the proper precautions and reduction in risk factors 
(vaccination, condom use, limiting number of sexual partners, etc.), their chances of acquiring 
HPV could be reduced (CDC, 2015j).  
 A question that did not see much of an increase in the pre-or post-survey asked who 
should receive the HPV vaccine (males, females, or both).  Almost 100% of students answered 
this question correctly, showing that a good majority of students had knowledge of this 
component of the HPV vaccine. This information correlates well with the question asking how if 
the students had ever heard of the HPV vaccine before, to which 27 (90.0%) students indicated 
they had.  
Belief, Attitude, and Barrier Questions 
 Belief, attitude, and barrier questions were addressed in the pre-and post-surveys to 
determine whether student’s views changed after education was provided. A majority of 
questions were designed to increase mean results, while a smaller number of questions were 
designed to decrease mean results (Figure 7, 8).  Questions designed to increase mean results in 
post-survey responses largely had the intended outcome. The question with the greatest positive 
change in post-survey mean (0.57) asked if students intended to receive the HPV vaccination 
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series in the future. The question with the second greatest change in post-survey mean (0.45) 
asked if students were motivated to maintain a healthy lifestyle.  These two questions correlate 
well because it shows students are motivated to be healthy as well as ready to take action to do 
so (intent to vaccinate). This response shows a very positive attitude and belief reaction to 
teaching and student comprehension of material.   
Only two questions in this category had the opposite response.  The first question (I 
believe that if I receive the HPV vaccine, I will be protected from cervical cancer) had the 
greatest reduction in mean response between the two.  This is interesting because another 
question in this category (I believe that if I receive the HPV vaccine, I will be protected against 
the most cancer-causing strains of HPV) received the third highest positive change in mean 
numbers (0.34).  This leads us to question if students were not aware that in women, HPV-
related cancers usually manifest as cervical cancer (70%), although it was a component 
addressed in the explanation of HPV-related cancers in the educational video (CDC, 2015j).  The 
other possibility is students were simply not paying attention at the beginning of the video, 
because the video mentions this fact within the first few minutes. The other question with a 
reduction in mean (It is preferable to be vaccinated rather than get the disease and be protected 
naturally), had a decrease in post-survey mean of only 0.02, so the numbers are very close to 
being the same.   
 Three questions were also designed to decrease mean results, having the intended 
response in one out of three questions. The belief question with the highest increased mean 
(0.34) in this category (I do not believe that HPV is exceptionally harmful) had a response which 
was not anticipated.  The first possibility to this response is after receiving education and 
learning how much protection the vaccination series offers from high-risk HPV strains (because 
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over half of participants were already vaccinated with the HPV vaccine series) they believed 
themselves protected from the cancer-causing strains and therefore did not believe it is a virus 
that is harmful to them. The second possibility is simply that the students require a greater 
amount of education for better understanding, which is supported by the third question in this 
category showing an anticipated decline in mean results asking students if they did not have 
enough information about HPV or the HPV vaccine.  The last question with a slight increase in 
mean (0.08) indicated cost would be a barrier, although the numbers are not significantly 
different.  
 Additional barrier questions which were addressed throughout other sections in the 
surveys revealed that health care coverage is not a barrier, as 100% of participants indicated a 
positive response. Although the type of health care coverage was not specified, one can 
reasonably assume many participants were still covered by their parent’s health insurance plans, 
as all participants were under the age of 26.  Healthcare providers offering to begin the HPV 
series was also determined not to be a barrier, as a majority of students indicated this had been 
offered to them.  As a future healthcare provider, it is encouraging to see such a good response to 
this question. The data also indicated that being busy with work and school was not a barrier, 
correlating well with the previously discussed question of being motivated to live a healthy 
lifestyle despite the busy life of a university student.    
Gender and Age Findings 
 Results were also divided into categories of gender and age. Gender question results were 
not as significant because there were only four male respondents and 26 female respondents.  
There were, however, a few noteworthy findings in the gender results. All four male respondents 
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were found to be smokers, placing them at higher risk for HPV-acquired cancers. Fifty percent of 
male respondents used condoms, but only 50% had sexual experience.  
 Age results were more significant because the two age groups were more evenly divided 
(ages 18-20 and 21-26).  There were a range of noteworthy findings in this category. A higher 
percentage of the older age group (81%) had completed the HPV series when compared to the 
younger age group (57%), and the younger age group showed a much higher belief in self-risk to 
acquire HPV (63%) when compared with the older age group (27%).  Therefore, the younger age 
group was less likely to be vaccinated with the HPV series and also more likely to engage in 
higher risk sexual activity than the older age group. Another possibility is this could be a 
reflection of learning from the video presentation, which indicated younger, unvaccinated 
individuals were at higher risk.  The older age group had a higher percentage of sexual 
experience (93%) when compared to the younger age group (64%), and a higher percentage of 
the older age group (31%) had been diagnosed with an STI compared to the younger age group 
(7%). These findings correlate well, as a higher amount of sexual activity promotes a higher risk 
for the acquisition of sexually transmitted complications.  Interesting to note, under half (26%) of 
older age group participants use a condom with sexual activity, compared to over half (60%) of 
younger age group participants. Most likely less of the older age group reported condom use 
because fifty percent reported being in a stable relationship when compared to only fourteen 
percent of younger age group participants. Over half of older age group participants (66%) had 
seen a gynecologist before as compared to less than half of younger age group participants (23%) 
had. Research indicates students who have never visited a gynecologist before have a greater 
likelihood to not be vaccinated with the HPV vaccine (Donadiki et al., 2014).  Oral contraceptive 
use was determined to be comparable.  
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Reassessment Surveys 
Reassessment surveys were sent out at three and six months to participants.  Twenty-five 
reassessment surveys were sent to participants at each three and sixth month.  The three-month 
surveys had a total of 10 surveys started, and seven completed with a completion rate of 70%.  
The six-month surveys had a total of nine surveys started, and seven completed with a 
completion rate of 78%.  The same seven students responded to each of both reassessment 
surveys, as could be noted by recorded anonymous codes identifying each student.  Three 
respondents indicated they would like more information about the HPV vaccine, showing the 
need for further education. Four students signified they would be more likely to receive the HPV 
vaccine now after attending the learning session earlier in the year, showing a good response to 
the education.  
Out of the seven respondents, six had been vaccinated with at least one of the HPV 
vaccine series doses, while one had not, and five indicated they had been fully vaccinated.  
While no students indicated they had received the HPV vaccine since education, two students 
indicated they intend to receive it in the future.  One of the goals of the reassessment surveys was 
to remind students about getting the HPV vaccine if they had not already completed it, so even 
though no participants indicated they had actually received the vaccine since education, it is 
encouraging two were still intending to receive it.  
Limitations 
 There were a few limitations to the project. Not all student participants completed all 
post-survey questions. It would have been more beneficial for data analysis to require students to 
select an answer before progressing. As currently designed, students did not have to answer any 
question they didn’t feel comfortable answering.  One student admitted to taking the pre-and 
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post-survey without viewing the video, which may have skewed some of the education and 
belief/barrier/attitude questions.  This was able to happen because the surveys were sent out to 
student groups one hour prior to the set meeting times. During the Sex Positivity Expo, there 
were problems with the surveys sending immediately for students to be able to take it right at the 
booth, so the goal was to prevent any complication if the surveys were to take longer to send 
(since it was sent out to a larger number of group participants).  It also may have been beneficial 
to do the question and answer discussion session right after students viewed the educational 
video, so the post-survey could have demonstrated more significant student learning outcomes.  
Recommendations 
Due to the positive outcome of increased intent to vaccinate found in the data of this 
practice improvement project, it would be beneficial to continue education on NDSU’s campus 
to various other student organizations.  The project falls into line with NDSU’s strategic plan for 
2015-2020 through collaboration with core values of educational excellence, cutting-edge 
scholarship, accountability, collaboration, and diversity (NDSU, 2015).  The program challenges 
students to excel not only in the classroom, but promotes learning through group activities 
outside the classroom, is supported by evidence-based research, and focuses on teaching students 
about primary prevention.  It also works to improve quality of life and is able to reach a variety 
of university students with diverse cultural backgrounds. 
The types of researchers recommended to continue future phases of this research include 
clinical professionals such as registered nurses, graduate student nurses, advanced practice 
nurses, medical students, or physicians. Those in the medical field have unsurpassed credibility 
when focusing on providing education about HPV prevention and catch-up vaccination.  HPV 
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education would be beneficial to be continued in the university/college setting, as well as the 
high school setting.   
Other settings which could benefit from this type of research include primary care clinics 
with the provision of education to primary care providers, or other clinic settings including 
family planning, community health centers, or clinics focusing on women’s health. Another good 
setting may be high schools, where young adults are within the target age group to receive the 
HPV vaccine series. 
Implications for Future Practice 
 After reviewing numerous research studies and the analyzing results of this practice 
improvement project, there are many implications for future practice in regard to HPV education, 
focusing on catch-up vaccination and reduction of risk factors to prevent HPV-related cancers 
and other sequelae.  As discussed previously, one of the belief questions with an unexpected 
outcome was an increase in positive post-survey response when students were asked if they did 
not believe HPV is exceptionally harmful.  Knowledge regarding prevalence of HPV has seemed 
to work against us by making it seem so common and therefore not as harmful.  Placing an extra 
emphasis on the importance of vaccination and prevention of associated HPV-related cancers 
and sequelae is necessary.  This result may also be due to the fact that over half of students were 
already vaccinated with the HPV series and therefore did not view HPV as a threat, or it might 
have indicated a need for further teaching.  To go along with this point, students indicated in 
both the post-survey and reassessment surveys that they wanted to know more about both HPV 
and the vaccine. 
 Assessment of healthcare provider roles in advocating for use of the HPV vaccine series 
revealed most students had been asked to begin the series by their provider.  Despite healthcare 
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providers having offered to start the series, or even students having already been vaccinated with 
the series, there is a need for more education outside of the clinic setting. Healthcare providers 
simply do not always have enough time to dedicate towards giving patients hesitant to receive 
the HPV vaccine education about it or explaining how vaccine monitoring systems (Vaccine 
Adverse Event Reporting System, Vaccine Safety Datalink, and Clinical Immunization Safety 
Assessment Project) are utilized to continually monitor HPV vaccine safety and efficacy (CDC, 
2015e).   The practice improvement project indicated 70% of NDSU students in the study sample 
were partially or fully vaccinated with the HPV series. This matches up well with the most recent 
state data, which gave North Dakota a range of 60-69% HPV vaccination coverage, and better 
than the national data coverage of 60% (CDC, 2017c).   Therefore, when compared with national 
and state data, NDSU students are more likely to be partially or fully vaccinated with the HPV 
series.  
From a different perspective, young adults who have been vaccinated will someday be 
parents and need to decide whether or not to vaccinate their children, so this improvement 
project and any future educational opportunities for young adults and parents will be beneficial 
to future practice with the goal of reducing the prevalence of HPV in society and reducing HPV-
related cancers. Newer evidence also shows that head and neck cancer is caused by HPV and less 
by alcohol and tobacco, and although it is more prevalent in males, can also affect females 
(American Cancer Society, 2016).    
 A question with great significance to the project inquired if students felt the education 
motivated them to engage in safer sexual practices in the future. All but one student replied 
positively to this question.  Promoting the use of education to allow students to be proactive in 
protecting their sexual health is beneficial to students for many reasons, but primarily for the 
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purpose of this project, preventing the acquisition of HPV-related cancers and sequelae and 
promoting the HPV catch-up vaccination series.  
 Plans to disseminate this research include presenting a poster at NDSU this spring.  I also 
plan on completing a three-minute video to be posted publicly for viewing on NDSU’s website 
in accordance with graduate school requirements.  In the future, I would also like to consider 
writing an article to submit to a sexual health journal.  
Implications for Future Research 
Future studies which focus on HPV education can benefit from methods and findings in 
previously completed research.  Recommendations for future research on this subject would be 
to focus primarily on increasing the population sample to receive the education.  During the 
working phase of this project when groups were being contacted to participate, communication 
was initiated with both a sorority and fraternity member at a poster presentation who were eager 
to have the HPV education presented in their affiliations.  However, no further contact was 
established after a few initial emails. Sororities and fraternities would be a great target audience 
on college campuses if one had the proper connections, as there are hundreds of potential 
participants. A question asking whether or not students would choose to vaccinate their children 
with the HPV vaccine series someday would be beneficial, as this could be a good indicator of 
long-term impact from the education.  This would also be a great question for those students who 
are already vaccinated with the series. 
There is a broad spectrum of other types of information that could be collected in order to 
make correlations between different variables. Further risk factors (alcohol/drug consumption, 
how many sexual encounters in the past year, number of past sexual partners, any comorbidities 
such as depression/loneliness, etc.) could be assessed.  Directly inquiring whether female 
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students over the age of 21 have received preventative pap smears (from their primary healthcare 
provider or a gynecologist) rather than just asking whether or not they had seen a gynecologist 
may also be beneficial. 
Application to Other DNP Roles 
 This practice improvement project can be applied to other DNP roles including leadership 
and advocacy.  Throughout the past few years, designing this evidence-based practice project has 
allowed for the maturity of leadership skills through development of communication with key 
stakeholders and study participants, and enhanced teaching skills used to motivate and inspire 
NDSU students to learn about HPV and the importance of the HPV vaccine.   The project has 
also allowed for student health advocacy by focusing on health promotion and preventative 
health measures in order to protect students from the harmful effects of HPV-related cancers.  
 Interprofessional collaboration was demonstrated through collaboration with health care 
professionals, such as working with the two registered nurses who also attended the Sex 
Positivity Expo and the Woman’s Activist Organization meeting in order to answer student 
questions.   Communication with leaders of NDSU student groups and leaders of student health 
affairs to participate in the study was also a demonstration of Interprofessional collaboration.  
 Translating evidence into practice is another DNP role which was fulfilled in the project. 
Through the development of research skills and searches conducted on multiple professional 
databases, evidence for benefits of HPV education and vaccine importance was proven.  Current 
research is ongoing to promote education and vaccine uptake.  New statistics have recently 
emerged about the prevalence of oral HPV among men (1:9), how the vaccine can possibly 
increase chance of conception, information about cervical cancer, new antibody testing to detect 
risk of developing oral HPV, and many more (Medical Life Science, 2017).  
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APPENDIX A. KEY STAKEHOLDERS AND RESOURCES 
 Key stakeholders for the clinical project include the presidents of each of the three NDSU 
organizations.  Each stakeholder was contacted via email to determine if their organization 
would be a good fit for the clinical project.  Contact was initially made via email with Kelsey 
Keimig, the Assistant Director of Sexual Assault Prevention and Advocacy and VPE president.  
After interest in the clinical project was established, an in-person meeting was held with her to 
discuss the details of the project.  Ms. Keimig then was able to refer me to the other two 
organizations (WAO and SST) who are the other two organizations participating in the clinical 
project.  Contact was then made with Olivia Oland (president of WAO) and Kailyn Ohm 
(president of SST).  They both agreed the clinical project would be a good fit for their 
organizations.  Ms. Oland recommended I participate in the SEXPO, which WAO hosts 
annually, and was able to reserve a booth for the HPV education for Spring 2017.   
 Another key stakeholder in the clinical project is Emily Hegg, the Health and Wellness 
Promotion Coordinator at Student Health Services.  A meeting was held with her initially to see 
if Student Health Services would be interested in having a representative present and possibly be 
able to administer the vaccine at the end of each education session if students wanted to receive 
it.  It was decided that having the vaccine present at the meetings would not be a viable option.  
However, she did advocate for having a Student Health Services representative present during 
the meetings in order to answer questions students may have about receiving the vaccine series 
through NDSU’s Student Health Service.   
    Needed resources included a place for the presentation, screen, projector, and laptop for 
the video presentation.  The screen and projector were located in each of the two group meeting 
rooms, and the researcher provided the laptop.  Dates for implementation of education to each 
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organization were determined at the beginning of the 2017 spring semester.  Resources for the 
SEXPO include a booth, which was provided by the host of the event, the Woman’s Activist 
Organization.  
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APPENDIX B. PERMISSION TO USE RESEARCH 
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APPENDIX C. IRB APPROVAL 
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APPENDIX D. STUDENT PRE-INTERVENTION SURVEY 
Questions True/Yes False/No Unsure 
1. Human papillomavirus (HPV) is the most common sexually 
transmitted infection in the United States. 
    
 
2. It is estimated that nearly 100% of sexually active men and women 
will become infected with HPV at some point in their lifetime.   
    
 
3. If I am infected with HPV, I could get genital warts and/or cancer.      
4. The highest rates of new genital HPV infections occur in young 
adults in their late teens and early 20s. 
  
 
5. How is HPV transmitted? (Select all that apply) 
A. Skin-to-skin contact                                                                   B. Contact with infected blood  
C. An infected person coughs or sneezes on another person          D. Vaginal, oral, or anal sex 
 Males Females Both 
6. Who should receive the HPV vaccine?     
 Yes No Unsure/NA 
7. Have you completed a yearly physical or sports physical this year?     
8. Have you ever heard of the HPV vaccine before?    
9. Have you completed at least one of the HPV vaccine series of 3 
shots? 
   
10. Have you completed the entire HPV vaccine series?           
11. I believe I could be at risk (now or in the future) for getting HPV.    
12. I have someone I can talk to (parent, nurse, doctor, friend, teacher) 
about my questions and concerns about HPV and the HPV vaccine. 
   
13. I make sure to use a condom during any sexual activity.    
14. I have been diagnosed with a sexually transmitted infection 
before. 
   
15. I have had previous oral, anal, or vaginal sexual experience.    
16. I am currently in a stable relationship.    
17. I have visited a gynecologist in the past.    
18. I currently use contraceptives.    
19. I am currently a smoker.    
19. I currently have health insurance coverage.    
   (Barry, 2013; Donadiki et al, 2014; Pender et al., 2011) 
Questions Yes No 
I give my permission to participate in this study and attest I am at least 
18 years old. 
  
 Male Female 
I am a:    
I am in the age group of (select one): o 18-20 years’ old 
o 21-26 years’ old 
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   (Donadiki et al., 2014; Pender et al., 2011) 
 
  
Questions Absolutely 
Agree 
Agree Neutral Disagree Absolutely 
Disagree 
Not 
Applicable 
1. I believe that vaccinations are 
effective and do prevent diseases. 
      
2. It is preferable to be vaccinated 
rather then get the disease and be 
protected naturally 
      
3. It is important to receive all 
vaccines, including the HPV 
vaccine.  
      
4. I have confidence that the human 
papillomavirus (HPV) vaccine is 
safe.  
      
5. I believe that if I receive the 
HPV vaccine, I will be protected 
from cervical cancer.  
      
6. I have the knowledge and skills 
to make safe sexual choices. 
      
7.  Cost would influence the 
decision for me to receive the HPV 
vaccine. 
      
8. I believe that if I receive the 
HPV vaccine, I will be protected 
against the most cancer-causing 
strains of HPV. 
      
9.  I do not believe that HPV is 
exceptionally harmful. 
      
10.  I do not have enough 
information about HPV and/or the 
HPV vaccine. 
      
11. I intend to receive the HPV 
vaccination series in the future. 
      
12. I am motivated to maintain a 
healthy lifestyle. 
      
 81 
APPENDIX E. STUDENT POST-INTERVENTION SURVEY 
 
 
Questions True/Yes False/No Unsure 
1. Human papillomavirus (HPV) is the most common sexually 
transmitted infection in the United States. 
    
 
2. It is estimated that nearly 100% of sexually active men and women 
will become infected with HPV at some point in their lifetime.   
    
 
3. If I am infected with HPV, I could get genital warts and/or cancer.      
4. The highest rates of new genital HPV infections occur in young 
adults in their late teens and early 20s. 
  
 
5. How is HPV transmitted? Select all that apply. 
A. Skin-to-skin contact                                                                   B. Contact with infected blood  
C. An infected person coughs or sneezes on another person          D. Vaginal, oral, or anal sex 
 Males Females Both 
6. Who should receive the HPV vaccine?     
 Yes No Unsure 
7. I believe I could be at risk (now or in the future) for getting HPV.    
8.  If you choose, please provide an explanation of why you do or do 
not believe in the HPV vaccine. 
 
 
 
 
9. How reliable did you find the informational video that you saw? 
1    Not at all reliable  
2    Slightly reliable 
3     Reliable 
4     Very reliable 
Do you feel this education has motivated you to engage in safer 
sexual practices in the future? 
                YES                      NO 
   (Barry, 2013; Donadiki et al., 2014) 
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(Donadiki et al., 2014; Pender et al., 2011) 
 
Please enter your email address for a chance to win a $50 Walmart gift card.  You will also be 
sent 3 and 6-month reassessment surveys to assess your vaccination status if you have not 
previously received or completed the HPV vaccine series. Each additional survey reply will give 
you another entry for your chance to win a Walmart gift 
card. _____________________________________________________ 
Thank you for your participation! 
Questions Absolutely 
Agree 
Agree Neutral Disagree Absolutely 
Disagree 
Not 
Applicable 
1. I believe that vaccinations are effective 
and do prevent diseases. 
      
2. It is preferable to be vaccinated rather 
then get the disease and be protected 
naturally 
      
3. It is important to receive all vaccines, 
including the HPV vaccine.  
      
4. I have confidence that the human 
papillomavirus (HPV) vaccine is safe.  
      
5. I believe that if I receive the HPV 
vaccine, I will be protected from cervical 
cancer.  
      
6. I have the knowledge and skills to make 
safe sexual choices. 
      
7.  Cost would influence the decision for 
me to receive the HPV vaccine. 
      
8. I believe that if I receive the HPV 
vaccine, I will be protected against the most 
cancer-causing strains of HPV. 
      
9.  I do not believe that HPV is 
exceptionally harmful. 
      
10.  I do not have enough information about 
HPV and/or the HPV vaccine. 
      
11. My healthcare provider has offered to 
begin the HPV vaccine series for me.  
      
12. I am too busy with school/work/friends 
to go see a healthcare provider. 
      
13. I intend to receive the HPV vaccination 
series in the future. 
      
14. I am motivated to maintain a healthy 
lifestyle. 
      
15. My parents believe in receiving all 
vaccines, including the HPV vaccine. 
      
16. My friends believe in receiving all 
vaccines, including the HPV vaccine.  
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APPENDIX F. STUDENT 3 AND 6-MONTH REASSESSMENT SURVEYS 
 
Questions Yes No Unsure/NA 
Did the human papillomavirus (HPV) education 
provided earlier in the year make you more likely to 
receive this vaccine? 
   
Were you vaccinated with any part of the HPV vaccine 
series before the HPV education was given?  
   
Have you made an appointment with Student Health 
Services or your healthcare provider to start the HPV 
vaccine series since receiving the HPV education? 
   
Have you been vaccinated with at least 1 dose of the 
HPV vaccine series since receiving information about 
HPV? 
   
If not currently vaccinated for HPV, do you plan on 
receiving it in the future? 
   
I was already fully vaccinated for HPV at the time of 
education.  
   
I am not interested in receiving the HPV vaccine.    
I would like to receive more information about HPV 
and the HPV vaccine. 
   
 
Thank you, your name has been entered for a drawing for a $50 Walmart gift card! 
 
Please visit the following CDC website if you have any additional questions or concerns about 
HPV or the HPV vaccine series: https://www.cdc.gov/hpv/ 
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APPENDIX G. STUDENT HANDOUTS 
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(CDC, 2016e) 
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APPENDIX H. VOICETHREAD PRESENTATION 
 
Students, 
 
Thank you for your participation. Additional information including material about the newest 
vaccine Gardisil-9 covering 9 sub-types can be found at the following link: 
https://voicethread.com/share/8573996/. 
 
Best regards, 
 
Sarah Siebert, BSN, RN, DNP-Student 
NDSU College of Nursing 
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APPENDIX I. HPV POSTER PRESENTATION 
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APPENDIX J. COLLECTIVE RESULTS 
 
 
I am a:  Male (N=4) Female (N=26) Total (N=30) 
I am in the age 
group of: 
o Age 18-20 (N=14) 
o 21-26 years old (N=16) 
Questions True/Yes False/No Unsure 
 Pre Post Pre Post Pre Post 
1. Human papillomavirus 
(HPV) is the most 
common sexually 
transmitted infection in 
the United States. 
63.33% 
N=19 
84.00% 
N=21 
23.33% 
N =7 
12.00% 
N=3 
13.33% 
N=4 
4.00% 
N=1 
2. It is estimated that 
nearly 100% of sexually 
active men and women 
will become infected 
with HPV at some point 
in their lifetime.   
26.67% 
N=8       
88.00% 
N=22 
53.33% 
N=16 
12.00% 
N=3 
 
20.00% 
 
N=6 
% 
N= 
3. If I am infected with 
HPV, I could get genital 
warts and/or cancer. 
83.33% 
 
N=25 
 
96.00% 
 
N=24 
6.67% 
 
N=2 
4.00% 
 
N=1 
10.00% 
 
N=3 
 
4. The highest rates of 
new genital HPV 
infections occur in young 
adults in their late teens 
and early 20s. 
90.00% 
N= 27 
88.00% 
N=22 
6.67% 
N=2 
4.00% 
N=1 
3.33% 
N=1 
8.00% 
N=2 
5. How is HPV transmitted? (Select all that apply) 
A. Skin-to-skin contact                                                                   B. Contact with infected blood  
C. An infected person coughs or sneezes on another person          D. Vaginal, oral, or anal sex 
Pretest Posttest 
 D 50.00% (N=15), A&D 43.33% (N=13), B&C 6.67% (N=2)    D 24.00% (N=6), A&D 72.00% (N=18), B&C 4.00% (N=1) 
 Males Females Both 
 Pre Post Pre Post Pre Post 
6. Who should receive 
the HPV vaccine?   
6.67% 
N=2 
4.00% 
N=1 
93.33% 
N=28 
96.24% 
N=24 
 
Yes No Unsure/NA 
Pre Post Pre Post Pre Post 
7. Have you completed a 
yearly physical or sports 
physical this year?  
46.67%        
N=14 
NA 
 
50.00%             
N=15 
NA 3.33%             
N=1 
NA 
8. Have you ever heard 
of the HPV vaccine 
before? 
90.00% 
N=27 
NA 
 
6.67% 
N=2 
NA 3.33% 
N=1 
NA 
 
Yes No Unsure 
Pre Post Pre Post Pre Post 
9. Have you completed at 
least one of the HPV 
vaccine series of 3 shots? 
73.33%        
N=22 
NA 
 
13.33%         
N=4 
NA 
 
13.33%        
N=4 
NA 
 
 89 
 
Yes No Unsure 
Pre Post Pre Post Pre Post 
10. Have you completed 
the entire HPV vaccine 
series?        
70.00%        
N=21 
NA 
 
16.67%        
N=5 
NA 
 
13.33%        
N=4 
NA 
 
11. I believe I could be at 
risk for getting HPV. 
46.43% 
N=13          
45.45% 
N=10 
42.86% 
N=12 
50.00% 
N=11            
10.71%    
N=3 
4.55% 
N=1 
12. I have someone I can 
talk to (parent, nurse, 
doctor, friend, teacher) 
about my questions and 
concerns about HPV and 
the HPV vaccine. 
89.66%      
N=26 
NA 
 
6.90%         
N=2 
NA 
 
3.45%         
N=1 
NA 
13. I make sure to use a 
condom during any 
sexual activity. 
40%          
N=10 
NA 
 
48.00%            
N=12 
 NA 
 
12.00%              
N=3 
NA 
 
14. I have been 
diagnosed with a 
sexually transmitted 
infection before. 
20.00%         
N=6 
NA 
 
80.00%        
N=24 
NA 
 
0%            
N=0 
NA 
 
15. I have had previous 
oral, anal, or vaginal 
sexual experience. 
80.00%      
N=24 
NA 
 
20.00%       
N=6 
NA 
 
0%             
N=0 
NA 
 
16. I am currently in a 
stable relationship. 
33.33%      
N=10 
NA 
 
66.67%       
N=20 
NA 
 
0%            
N=0 
            NA 
 
17. I have visited a 
gynecologist in the past. 
46.43%      
N=13 
NA 
 
53.57%       
N=15 
NA 
 
0%             
N=0 
NA 
 
18. I currently use oral 
contraceptives. 
37.04%       
N=10 
NA 
 
62.96%       
N=17 
NA 
 
0%             
N=0 
NA 
 
19. I am currently a 
smoker. 
6.67%       
N=2 
NA 
 
90.00%       
N=27 
NA 
 
3.33%          
N=1 
NA 
 
19. I currently have 
health insurance 
coverage. 
100%         
N=30 
NA 
 
    
 Very Reliable Reliable Slightly Reliable 
20. How reliable did you 
find the informational 
video that you saw? 
72.00% 
N=18 
 
24.00% 
N=6 
4.00% 
N=1 
 Yes No 
21. Do you feel this 
education has motivated 
you to engage in safer 
sexual practices in the 
future? 
96.00% 
N=24 
 
4.00% 
N=1 
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Questions Absolutely Agree 
(5pt) 
Agree 
(4pt) 
Neutral 
(3pt) 
Disagree 
(2pt) 
Absolutely Disagree 
(1pt) 
 Pre Post Pre Post Pre Post Pre Post Pre Post 
1. I believe that 
vaccinations 
are effective 
and do prevent 
diseases. 
 
83.33% 
 
N=25 
 
92.00% 
 
 N=23 
 
13.33% 
 
N=4 
4.00% 
 
N=1 
3.33% 
 
N=1 
4.00% 
 
N=1 
    
2. It is 
preferable to be 
vaccinated 
rather then get 
the disease and 
be protected 
naturally 
90.00% 
 
N=27 
92.00% 
 
N=23 
10.00% 
 
N=3 
8.00% 
 
N=2 
      
3. It is 
important to 
receive all 
vaccines, 
including the 
HPV vaccine.  
73.33% 
 
N=22 
 
88.00% 
 
N=22 
23.33% 
 
N=7 
12.00% 
 
N=3 
3.33% 
 
N=1 
     
4. I have 
confidence that 
the human 
papillomavirus 
(HPV) vaccine 
is safe.  
66.67% 
 
N=20 
76.00% 
 
N=19 
23.33% 
 
N=7 
20.00% 
 
N=5 
6.67% 
 
N=2 
 
 
3.33% 
 
N=1 
   
5. I believe that 
if I receive the 
HPV vaccine, I 
will be 
protected from 
cervical cancer.  
33.33% 
 
N=10 
41.63% 
 
N=10 
40.00% 
 
N=12 
33.33% 
 
N=8 
6.67% 
 
N=2 
12.50% 
 
N=3 
20.00% 
 
N=6 
12.50% 
 
N=3 
  
6. I have the 
knowledge and 
skills to make 
safe sexual 
choices. 
73.33% 
 
N=22 
88.00% 
 
N=22 
23.33% 
 
N=7 
 
12.00% 
 
N=3 
3.33% 
 
N=1 
     
7.  Cost would 
influence the 
decision for me 
to receive the 
HPV vaccine. 
13.79% 
 
N=4 
13.04% 
 
N=3 
27.59% 
 
N=8 
 
43.48% 
 
N=10 
20.69% 
 
N=6 
13.04% 
 
N=3 
27.59% 
 
N=8 
13.04% 
 
N=3 
10.34% 
 
N=3 
17.39% 
 
N=4 
8. I believe that 
if I receive the 
HPV vaccine, I 
will be 
protected 
against the 
most cancer-
causing strains 
of HPV. 
40.00% 
 
N=12 
66.67% 
 
N=16 
 
 
 
 
43.33% 
 
N=13 
29.17% 
 
N=7 
10.00% 
 
N=3 
4.17% 
 
N=1 
3.33% 
 
N=1 
 3.33% 
 
N=1 
 
9.  I do not 
believe that 
HPV is 
exceptionally 
harmful. 
10.00% 
 
N=3 
25.00% 
 
N=6 
10.00% 
 
N=3 
 
16.67% 
 
N=4 
6.67% 
 
N=2 
 46.70% 
 
N=14 
33.33% 
 
N=8 
26.67% 
 
N=8 
25.00% 
 
N=6 
10.  I do not 
have enough 
information 
about HPV 
and/or the HPV 
vaccine. 
6.90% 
 
N=2 
20.83% 
 
N=5 
 
 
13.79% 
 
N=4 
4.17% 
 
N=1 
37.93% 
 
N=11 
8.33% 
 
N=2 
27.59% 
 
N=8 
41.67% 
 
N=10 
13.79% 
 
N=4 
25.00% 
 
N=6 
11. My 
healthcare 
provider has 
offered to begin 
the HPV 
vaccine series 
for me.  
Post Only: 
66.67% 
N=12 
Post 
Only: 
11.11% 
N=2 
Post  
Only: 
11.11% 
N=2 
 Post Only: 
11.11% 
N=2 
12. I am too 
busy with 
school/work/fri
ends to go see a 
healthcare 
provider. 
Post Only: 
4.17% 
N=1 
Post Only: 
16.67% 
N=4 
Post Only: 
4.17% 
N=1 
Post Only: 
50.00% 
N=12 
Post Only: 
25.00% 
N=6 
13. I intend to 
receive the 
HPV 
vaccination 
series in the 
future. 
23.08% 
 
N=3 
60.00% 
 
N=6 
 
 
23.08% 
 
N=3 
20.00% 
 
 N-2 
38.46% 
 
N=5 
 7.69% 
 
N=1 
10.00% 
 
N=1 
7.69% 
 
N=1 
10.00% 
 
N=1 
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Questions Absolutely Agree 
(5pt) 
Agree 
(4pt) 
Neutral 
(3pt) 
Disagree 
(2pt) 
Absolutely Disagree 
(1pt) 
 Pre Post Pre Post Pre Post Pre Post Pre Post 
14. I am 
motivated to 
maintain a 
healthy 
lifestyle. 
40.00% 
 
N=12 
58.33% 
 
N=14 
50.00% 
 
N=15 
37.50% 
 
N=9 
6.67% 
 
N=2 
 3.33% 
 
N=1 
4.17% 
 
N=1 
  
15. My parents 
believe in 
receiving all 
vaccines, 
including the 
HPV vaccine. 
Post Only: 
83.33% 
N=20 
Post Only: 
12.50% 
N=3 
  Post Only: 
4.17% 
N=1 
16. My friends 
believe in 
receiving all 
vaccines, 
including the 
HPV vaccine.  
Post Only: 
50.00% 
N=12 
Post Only: 
33.33% 
N=8 
 
 
Post Only: 
12.50% 
N=3 
Post Only: 
4.17% 
N=1 
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APPENDIX K. GENDER RESULTS 
 
 
I am a:  Male (N=4) Female (N=26) Total (N=30) 
I am in the age 
group of: 
 
o Age 18-20 (N=14) 
o 21-26 years’ old (N=16) 
Questions True/Yes False/No Unsure 
 
Male Female Male Female Male Female 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
1. Human 
papillomavirus (HPV) is 
the most common 
sexually transmitted 
infection in the United 
States. 
  50%      75% 
  N=2         N=3 
 65.38%   85.72% 
  N=17        N=18 
   0%         25% 
  N =0        N=1 
  26.92%      9.52% 
  N= 7        N=2 
    50%         0% 
    N=2          
  7.69%       4.76% 
   N=2         N=1     
2. It is estimated that 
nearly 100% of sexually 
active men and women 
will become infected 
with HPV at some point 
in their lifetime.   
 25%        100% 
   N=1        N=4 
  26.92%   85.72% 
  N=7        N=18 
   75%        0% 
   N=3       N=0  
 50%        14.28% 
   N=13         N=3 
   
    23.08%         0% 
   N=6             
3. If I am infected with 
HPV, I could get genital 
warts and/or cancer. 
 
  50%         75% 
  N=2         N=3 
  
  88.46%    100% 
  N=23       N=21 
   
  25%         25% 
  N=1         N=1 
  
  3.85%        
   N=1          
   
  25%           0% 
   N=1          N=0 
 
  7.69%          0% 
   N=2          N=0 
4. The highest rates of 
new genital HPV 
infections occur in 
young adults in their late 
teens and early 20s. 
  75%        100% 
 N= 3       N= 4 
 92.31%    85.72% 
   N=24       N=18 
   0%         0% 
   N=0       N=0        
   7.69%      4.76% 
 N=2        N=1 
  25%           0% 
   N= 1         N=0 
    0%        9.52% 
    N=0         N=2 
5. How is HPV transmitted? (Select all that apply)  
A. Skin-to-skin contact                                                                   B. Contact with infected blood  
C. An infected person coughs or sneezes on another person          D. Vaginal, oral, or anal sex 
Pretest Posttest 
Males Female Males Females 
D 75% (N=3), A&D 25% (N=1)     
D 46% (N=12), A&D 46% 
(N=12), B&C 8% (N=2)    
D 50% (N=2), A&D 50% (N=2)                    
D 23% (N=4), A&D 62% (N=16) 
B&C 4% (N=1) 
 Males Females Both 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
6. Who should receive 
the HPV vaccine?  
   
 
   
 
  
    8%             5% 
   N= 2           N=1 
 100%       100% 
   N=4       N=4 
 92%         95% 
   N=24       N=20 
 
Yes No Unsure/NA 
Male Female Male Female Male Female 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
7. Have you completed a 
yearly physical or sports 
physical this year?  
   50%        NA 
  N=2 
 46.15%         NA 
  N=12 
 50%            NA 
  N=2 
  50%             NA 
  N=13 
 
 
             
     
  3.85%                
   N=1 
8. Have you ever heard 
of the HPV vaccine 
before? 
 50% 
  N=2 
96.15% 
  N=25 
25% 
  N=1 
 3.85% 
  N=1 
25% 
 N=1 
 
 
 93 
 
Yes No Unsure 
Male Female Male Female Male Female 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
9. Have you completed 
at least one of the HPV 
vaccine series of 3 
shots? 
50%       NA 
 N=2    
76.92%       NA 
 N=20 
25%         NA 
 N=1 
11.54%        NA 
 N=3 
25%       NA 
 N=1 
 11.54%        NA 
 N=3 
10. Have you completed 
the entire HPV vaccine 
series?        
50%       NA 
 N=2 
73.08%       NA 
 N=19 
25%       NA 
 N=1 
15.38%        NA 
 N=4 
25%       NA 
 N=1 
 11.54%        NA 
 N=3 
11. I believe I could be 
at risk for getting HPV. 
33.3%   33.44% 
  N=1         N=1 
48%         47.34% 
  N=12          N=9 
66.67%   66.89% 
   N=2       N=2 
 40%        47.34% 
  N=10          N=9 
    
 
  12%          5.26% 
  N=3         N=1 
12. I have someone I can 
talk to (parent, nurse, 
doctor, friend, teacher) 
about my questions and 
concerns about HPV and 
the HPV vaccine. 
   100%     NA 
  N= 4       
  88.46%       NA 
  N=23 
 
  7.69%       NA 
  N=2 
   
  
  3.85%          NA 
  N=1 
13. I make sure to use a 
condom during any 
sexual activity. 
  50%         NA 
 N=2 
  39.13%       NA 
 N=9 
  
  
52.17%        NA 
 N=12 
   50%             NA 
 N=2 
  8.70%         NA 
 N=2 
14. I have been 
diagnosed with a 
sexually transmitted 
infection before. 
 
 23.08%       NA 
 N=6 
 100%       NA 
 N=4 
 76.92%        NA 
 N=20 
    
 
   
 
15. I have had previous 
oral, anal, or vaginal 
sexual experience. 
 50%     NA 
 N=2 
 84.62%       NA 
 N=22 
 50%      NA 
 N=2 
 15.38%         NA 
 N=4 
  
 
   
 
16. I am currently in a 
stable relationship. 
   25%        NA 
   N=1 
 34.62%        NA 
 N=9 
 75%      NA 
 N=3 
  65.38%        NA 
 N=17 
    
 
 
17. I have visited a 
gynecologist in the past. 
 NA 
   50%       NA 
   N=13 
 NA 
   50%         NA 
    N=13 
 
   
 
18. I currently use oral 
contraceptives. 
NA 
   40%        NA 
   N=10 
 NA 
     60%       NA 
     N=15 
    
 
   
 
19. I am currently a 
smoker. 
100%      NA 
 N=4 
  7.69%         NA 
 N=2 
  
 
 88.46%          NA 
 N=23 
  
 
  3.85%           NA 
 N=1 
19. I currently have 
health insurance 
coverage. 
 100%        NA 
 N=4 
 100%          NA 
 N=26 
    
 Male Female Male Female Male Female 
 Very Reliable Reliable Slightly Reliable 
20. How reliable did you 
find the informational 
video that you saw? 
75% 
N=3 
71% 
N=15 
 
 
29% 
N=6 
25% 
N=1 
 
 Male Female 
 Yes No Yes No 
21. Do you feel this 
education has motivated 
you to engage in safer 
sexual practices in the 
future? 
100% 
N=4 
 
95% 
20 
5% 
N=1 
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Questions Absolutely Agree 
(5pts) 
Agree 
(4pts) 
Neutral 
(3pts) 
Disagree 
(2pts) 
Absolutely Disagree 
(1pt) 
 Male Female Male Female Male Female Male Female Male Female 
1. I believe 
that 
vaccinations 
are effective 
and do 
prevent 
diseases. 
Pre: 
75% 
N=3 
Post: 
75% 
N=3 
 
Pre: 
84.62% 
N=22 
Post: 
95.24% 
N=20 
Pre: 
25% 
N=1 
Post: 
25% 
N=1 
Pre: 
11.53% 
N=3 
 Pre: 
3.84% 
N=1 
Post: 
4.76% 
N=1 
    
2. It is 
preferable to 
be vaccinated 
rather then 
get the 
disease and 
be protected 
naturally 
Pre: 
100% 
N=4 
Post: 
75% 
N=3 
Pre: 
88.47% 
N=23 
Post: 
95.24% 
N=20 
 
Pre: 
0% 
N=0 
Post: 
25% 
N=1 
Pre: 
11.53% 
N=3 
Post: 
4.76% 
N=1 
      
3. It is 
important to 
receive all 
vaccines, 
including the 
HPV vaccine.  
Pre: 
75% 
N=3 
Post: 
100% 
N=4 
Pre: 
73.09% 
N=19 
Post: 
85.72% 
N=18 
Pre: 
25% 
N=1 
Pre: 
23.07% 
N=6 
Post: 
14.28% 
N=3 
 Pre: 
3.84% 
N=1 
    
4. I have 
confidence 
that the 
human 
papillomavir
us (HPV) 
vaccine is 
safe.  
Pre: 
75% 
N=3 
Post: 
100% 
N=4 
 
Pre: 
65.40% 
N=17 
Post: 
71.44% 
N=15 
Pre: 
25% 
N=1 
Pre: 
23.07% 
N=6 
Post: 
23.80% 
N=5 
 Pre: 
7.69% 
N=2 
 Pre: 
3.84% 
N=1 
Post: 
4.76% 
N=1 
  
5. I believe 
that if I 
receive the 
HPV vaccine, 
I will be 
protected 
from cervical 
cancer.  
Pre: 
75% 
N=3 
Post: 
100% 
N=3 
Pre: 
26.91% 
N=7 
Post: 
33.32% 
N=7 
Pre: 
25% 
N=1 
Pre: 
42.29% 
N=11 
Post: 
38.08% 
N=8 
 
 Pre: 
7.69% 
N=2 
Post: 
14.28% 
N=3 
 Pre: 
23.07% 
N=6 
Post: 
14.28% 
N=3 
  
6. I have the 
knowledge 
and skills to 
make safe 
sexual 
choices. 
Pre: 
75% 
N=3 
Post: 
100% 
N=4 
Pre: 
73.09% 
N=19 
Post: 
85.72% 
N=18 
Pre: 
25% 
N=1 
Pre: 
23.07% 
N=6 
Post: 
14.28% 
N=3 
 
 
 
 
 
 
 
Pre: 
3.84% 
N=1 
    
7.  Cost 
would 
influence the 
decision for 
me to receive 
the HPV 
vaccine. 
 Pre: 
15.99% 
N=4 
Post: 
14.99% 
N=3 
Pre: 
50% 
N=2 
Post: 
66.56% 
N=2 
Pre: 
23.99% 
N=6 
Post: 
39.98% 
N=8 
Pre: 
25% 
N=1 
 
 
 
 
Pre: 
19.99% 
N=5 
Post: 
14.99% 
N=3 
Pre: 
25% 
N=1 
Post: 
33.44% 
N=1 
Pre: 
27.99% 
N=7 
Post: 
10.00% 
N=2 
 Pre: 
12.00% 
N=3 
Post: 
19.99% 
N=4 
8. I believe 
that if I 
receive the 
HPV vaccine, 
I will be 
protected 
against the 
most cancer-
causing 
strains of 
HPV. 
Pre: 
50% 
N=2 
Post: 
100% 
N=3 
Pre: 
38.45% 
N=10 
Post: 
61.88% 
N=13 
Pre: 
50% 
N=2 
Pre: 
42.29% 
N=11 
Post: 
33.32% 
N=7 
 Pre: 
11.53% 
N=3 
Post: 
4.76% 
N=1 
 Pre: 
3.84% 
N=1 
 Pre: 
3.84%=1 
N 
9.  I do not 
believe that 
HPV is 
exceptionally 
harmful. 
Pre: 
25% 
N=1 
Post: 
66.56% 
N=2 
Pre: 
7.69% 
N=2 
Post: 
19.04% 
N=4 
Pre: 
25% 
N=1 
Pre: 
7.69% 
N=2 
Post: 
19.04% 
N=4 
 
 Pre: 
7.69% 
N=2 
Pre: 
0% 
N=0 
Post: 
33.44% 
N=1 
Pre: 
53.86% 
N=14 
Post: 
33.32% 
N=7 
Pre: 
50% 
N=2 
Pre: 
23.07% 
N=6 
Post: 
28.56% 
N=6 
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Questions Absolutely Agree 
(5pt) 
Agree 
(4pt) 
Neutral 
(3pt) 
Disagree 
(2pt) 
Absolutely Disagree 
(1pt) 
 Male Female Male Female Male Female Male Female Male Female 
10.  I do not 
have enough 
information 
about HPV 
and/or the 
HPV vaccine. 
Pre: 
0% 
Post: 
33.44% 
N=1 
Pre: 
8% 
N=2 
Post: 
19.04% 
N=4 
Pre: 
25% 
N=1 
Pre: 
12% 
N=3 
Post: 
4.76% 
N=1 
Pre: 
25% 
N=1 
Pre: 
39.98% 
N=10 
Post: 
9.52% 
N=2 
Pre: 
25% 
N=1 
Post: 
33.44% 
N=1 
Pre: 
27.99% 
N=7 
Post: 
42.84% 
N=9 
Pre: 
25% 
N=1 
Post: 
33.44% 
N=1 
Pre: 
12% 
N=3 
Post: 
23.80% 
N=5 
11. My 
healthcare 
provider has 
offered to 
begin the 
HPV vaccine 
series for me.  
Post 
Only: 
100% 
N=2 
Post Only: 
62.46% 
N=10 
 Post 
Only: 
12.49% 
N=2 
 Post 
Only: 
12.49% 
N=2 
   Post 
Only: 
12.49% 
N=2 
12. I am too 
busy with 
school/work/f
riends to go 
see a 
healthcare 
provider. 
 Post Only: 
4.76% 
N=1 
 Post 
Only: 
19.04% 
N=4 
Post 
Only: 
33.44% 
N=1 
 Post 
Only: 
33.44% 
N=1 
Post 
Only: 
52.36% 
N=11 
Post 
Only: 
33.44% 
N=1 
Post 
Only: 
23.80% 
N=5 
13. I intend 
to receive the 
HPV 
vaccination 
series in the 
future. 
Pre: 
0% 
N=0 
Post: 
100% 
N=2 
Pre: 
29.97% 
N=3 
Post: 
50% 
N=4 
Pre: 
66.89% 
N=2 
Pre: 
9.99% 
N=1 
Post: 
25% 
N=2 
Pre: 
33.44% 
N=1 
Pre: 
39.96% 
N=4 
 Pre: 
9.99% 
N=1 
Post: 
12.50% 
N= 
 Pre: 
9.99% 
N=1 
Post: 
12.50% 
N= 
14. I am 
motivated to 
maintain a 
healthy 
lifestyle. 
Pre: 
0% 
N=0 
Post: 
33.44
% 
N=1 
Pre: 
46.14% 
N=12 
Post: 
61.88% 
N=13 
Pre: 
75% 
N=3 
Post: 
66.56% 
N=2 
Pre: 
46.14% 
N=12 
Post: 
33.32% 
N=7 
Pre: 
25% 
N=1 
Pre: 
3.84% 
N=1 
 Pre: 
3.84% 
N=1 
Post: 
4.76% 
N=1 
  
15. My 
parents 
believe in 
receiving all 
vaccines, 
including the 
HPV vaccine. 
Post 
Only: 
100% 
N=3 
 
 
Post Only: 
80.96% 
N=17 
 Post 
Only: 
14.28% 
N=3 
     Post 
Only: 
4.76% 
N=1 
16. My 
friends 
believe in 
receiving all 
vaccines, 
including the 
HPV vaccine.  
Post 
Only: 
33.44% 
N=1 
Post Only: 
52.36% 
N=11 
Post 
Only: 
66.56% 
N=2 
Post 
Only: 
28.56% 
N=6 
 Post 
Only: 
14.28% 
N=3 
 Post 
Only: 
4.76% 
N=1 
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APPENDIX L. AGE RESULTS 
 
I am a:  Male (N=4) Female (N=26) Total (N=30) 
I am in the age 
group of:  
o Age 18-20 (N=14) 
o 21-26 years old (N=16) 
Questions True/Yes False/No Unsure 
 
Age 18-20 Age 21-26 Age 18-20 Age 21-26 Age 18-20 Age 21-26 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
1. Human papillomavirus 
(HPV) is the most 
common sexually 
transmitted infection in 
the United States. 
 64.29%   78.57% 
  N=9         N=11 
 62.50%   90.91% 
  N=10        N=10 
  21.43% 14.29% 
 N =3       N=2 
  25%         9.09% 
  N=4          N=1 
 14.29%      7.14% 
  N=2          N=1 
 12.50%         0% 
   N=2         N=0     
2. It is estimated that 
nearly 100% of sexually 
active men and women 
will become infected 
with HPV at some point 
in their lifetime.   
 28.57%   92.86% 
   N=4        N=13 
  25%      81.82% 
  N=4        N=9 
   50%       7.14% 
  N=7       N=1 
56.25%     18.18% 
   N=9          N=2 
   
  21.43%        0% 
 
   N=3          N=0 
  18.75%         0% 
   N=3            N=0 
3. If I am infected with 
HPV, I could get genital 
warts and/or cancer. 
 
85.71%      100% 
  N=12       N=14 
  
81.25%    90.91% 
  N=13       N=10 
   
 7.14%        0% 
  N=1          N=0 
  
6.25%       9.09% 
   N=1          N=1 
   
  7.14%           0% 
   N=1           N=0 
 
12.50%          0% 
   N=2         N=0 
4. The highest rates of 
new genital HPV 
infections occur in young 
adults in their late teens 
and early 20s. 
85.71%    85.71% 
 N= 12       N=12  
 93.75%    90.91% 
   N=15       N=10 
 14.29%    7.14% 
  N=2         N=1 
   0%             0% 
     N=0        N=0 
  0%           7.14% 
   N= 0         N=1 
 6.25%        9.09% 
  N=1           N=1 
5. How is HPV transmitted? (Select all that apply)  
A. Skin-to-skin contact                                                                   B. Contact with infected blood  
C. An infected person coughs or sneezes on another person          D. Vaginal, oral, or anal sex 
Pretest Posttest 
18-20  21-26 18-20 21-26 
D 43% (N=6), A&D 43% (N=6), 
B&C 14% (N=2)     
D 56% (N=9), A&D 44% (N=7) 
D 29% (N=4), A&D 64% (N=9), 
B&C 7% (N=1)                    
D 18% (N=2), A&D 82% (N=9)  
 Males Females Both 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
6. Who should receive 
the HPV vaccine?  
   
 
   
 
   7%           0% 
  N=1        N=0        
    6%             9% 
N= 1           N=1 
 93%       100% 
   N=13       N=14 
 94%         91% 
   N=15       N=10 
 
Yes No Unsure/NA 
Age 18-20 Age 21-26 Age 18-20 Age 21-26 Age 18-20 Age 21-26 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
7. Have you completed a 
yearly physical or sports 
physical this year?  
  42.86%       NA 
  N=6 
  50%           NA 
  N=8 
  50%            NA 
  N=7 
  50%             NA 
  N=8 
  7.14%            NA 
 N=1      
 0%               NA 
 N=0 
8. Have you ever heard 
of the HPV vaccine 
before? 
 78.57% 
  N=11 
100% 
  N=16 
14.29% 
  N=2 
 0% 
  N=0 
7.14% 
 N=1 
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Yes No Unsure 
Age 18-20 Age 21-26 Age 18-20 Age 21-26 Age 18-20 Age 21-26 
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post 
9. Have you completed at 
least one of the HPV 
vaccine series of 3 shots? 
64.29%       NA 
 N=9    
81.25%       NA 
 N=13 
7.14%         NA 
 N=1 
18.75%        NA 
 N=3 
28.57%       NA 
 N=4 
 0%             NA 
 N=0 
10. Have you completed 
the entire HPV vaccine 
series?        
57.14%       NA 
 N=8 
81.25%       NA 
 N=13 
14.29%       NA 
 N=2 
18.75%        NA 
 N=3 
28.57%       NA 
 N=4 
 0%            NA 
 N=0 
11. I believe I could be at 
risk for getting HPV. 
53.85%   63.64% 
  N=7          N=7 
40%         27.27% 
  N=6           N=3 
46.15%   36.36 % 
   N=6       N=4 
 40%        63.64% 
  N=6            N=7 
   0%           0% 
  N=0          N=0 
  20%          9.09% 
  N=3         N=1 
12. I have someone I can 
talk to (parent, nurse, 
doctor, friend, teacher) 
about my questions and 
concerns about HPV and 
the HPV vaccine. 
   92.86%     NA 
  N=13        
  86.67%       NA 
  N=13 
    0%        NA 
  N=0 
  13.33%       NA 
  N=2 
   7.14%        NA 
  N=1 
  0%              NA 
  N=0 
13. I make sure to use a 
condom during any 
sexual activity. 
  60%         NA 
 N=6 
  26.67%       NA 
 N=4 
 40%            NA 
 N=4 
53.33%         NA 
 N=8 
   0%             NA 
 N=0 
  20%            NA 
 N=3 
14. I have been 
diagnosed with a 
sexually transmitted 
infection before. 
 7.14%        NA 
 N=1 
 31.25%       NA 
 N=5 
 92.86%       NA 
 N=13 
 68.75%        NA 
 N=11 
   0%            NA  
 N=0 
  0%             NA 
 N=0 
15. I have had previous 
oral, anal, or vaginal 
sexual experience. 
 64.29%     NA 
 N=9 
 93.75%       NA 
 N=15 
 35.71%      NA 
 N=5 
 6.25%         NA 
 N=1 
   0%            NA 
 N=0       
  0%             NA 
 N=0 
16. I am currently in a 
stable relationship. 
 14.29%     NA 
 N=2 
 50%            NA 
 N=8 
 85.71%      NA 
 N=12 
 50%            NA 
 N=8 
   0%            NA 
 N=0 
  0%             NA 
 N=0 
17. I have visited a 
gynecologist in the past. 
 23.08%     NA 
 N=3 
 66.67%       NA 
 N=10 
 76.92%      NA 
 N=10 
 33.33%       NA 
 N=5 
   0%            NA 
 N=0 
  0%             NA 
 N=0 
18. I currently use 
contraceptives. 
38.46%      NA 
 N=5 
35.71%        NA 
 N= 5 
 61.54%      NA 
 N=8 
 64.29%       NA 
 N= 9 
   0%            NA 
 N=0 
  0%             NA 
 N=0 
19. I am currently a 
smoker. 
14.29%      NA 
 N=2 
 0%              NA 
 N=0  
 78.57%      NA 
 N=11 
 100%          NA 
 N=16 
 7.14%         NA 
 N=1 
  0%             NA 
 N=0 
19. I currently have 
health insurance 
coverage. 
 100%        NA 
 N=14 
 100%          NA 
 N=16 
    
 Ages 18-20 Ages 21-26 Ages 18-20 Ages 21-26 Ages 18-20 Ages 21-26 
 Very Reliable Reliable Slightly Reliable 
20. How reliable did you 
find the informational 
video that you saw? 
71% 
N=10 
73% 
N=8 
21% 
N=3 
27% 
N=3 
7% 
N=1 
0% 
N=0 
 Ages 18-20 Ages 21-26 
 Yes No Yes No 
21. Do you feel this 
education has motivated 
you to engage in safer 
sexual practices in the 
future? 
93% 
N=13 
7% 
N=1 
100% 
11 
0% 
N=0 
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Questions Absolutely Agree 
(5pts) 
Agree 
(4pts) 
Neutral 
(3pts) 
Disagree 
(2pts) 
Absolutely Disagree 
(1pt) 
 Age 
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
1. I believe that 
vaccinations 
are effective 
and do prevent 
diseases. 
Pre: 
85.71% 
N=12 
Post: 
92.86% 
N=13 
 
Pre: 
81.25% 
N=13 
Post: 
90.91% 
N=10 
Pre: 
14.29% 
N=2 
Post: 
7.14% 
N=1 
Pre: 
12.50% 
N=2 
 Pre: 
6.25% 
N=1 
Post: 
9.09% 
N=1 
    
2. It is 
preferable to be 
vaccinated 
rather then get 
the disease and 
be protected 
naturally 
Pre: 
92.86% 
N=13 
Post: 
85.71% 
N=12 
Pre: 
87.50% 
N=14 
Post: 
100% 
N=11 
Pre: 
7.14% 
N=1 
Post: 
14.29% 
N=2 
Pre: 
12.50% 
N=2 
Post: 
0% 
N=0 
 
      
3. It is 
important to 
receive all 
vaccines, 
including the 
HPV vaccine.  
Pre: 
71.43% 
N=10 
Post: 
85.71% 
N=12 
Pre: 
75% 
N=12 
Post: 
90.91% 
N=10 
 
Pre: 
21.43% 
N=3 
Post: 
14.29% 
N=2 
Pre: 
25% 
N=4 
Post: 
9.09% 
N=1 
Pre: 
7.14% 
N=1 
     
4. I have 
confidence that 
the human 
papillomavirus 
(HPV) vaccine 
is safe.  
Pre: 
71.43% 
N=10 
Post: 
78.57% 
N=11 
Pre: 
62.50% 
N=10 
Post: 
72.73% 
N=8 
Pre: 
28.57% 
N=4 
Post: 
21.43% 
N=3 
Pre: 
18.75% 
N=3 
Post: 
18.18% 
N=2 
 
 Pre: 
12.50% 
N=2 
 Pre: 
6.25% 
N=1 
Post: 
9.09% 
N=1 
  
5. I believe that 
if I receive the 
HPV vaccine, I 
will be 
protected from 
cervical cancer.  
Pre: 
35.71% 
N=5 
Post: 
50% 
N=7 
Pre: 
31.25% 
N=5 
Post: 
30% 
N=3 
Pre: 
42.86% 
N=6 
Post: 
28.57% 
N=4 
Pre: 
37.50% 
N=6 
Post: 
40% 
N=4 
 
Pre: 
7.14% 
N=1 
Post: 
7.14% 
N=1 
Pre: 
6.25% 
N=1 
Post: 
20% 
N=2 
Pre: 
14.29% 
N=2 
Post: 
14.29% 
N=2 
Pre: 
25% 
N=4 
Post: 
10% 
N=1 
  
6. I have the 
knowledge and 
skills to make 
safe sexual 
choices. 
Pre: 
57.14% 
N=8 
Post: 
85.71% 
N=12 
Pre: 
87.50% 
N=14 
Post: 
90.91% 
N=10 
Pre: 
35.71% 
N=5 
Post: 
14.29% 
N=2 
Pre:  
12.50% 
N=2 
Post: 
9.09% 
N=1 
 
Pre: 
7.14% 
N=1 
     
7.  Cost would 
influence the 
decision for me 
to receive the 
HPV vaccine. 
Pre: 
14.29% 
N=2 
Post: 
15.38% 
N=2 
Pre: 
13.33% 
N=2 
Post: 
10% 
N=1 
Pre: 
35.71% 
N=5 
Post: 
46.15% 
N=6 
Pre:  
20% 
N=3 
Post: 
40% 
N=4 
Pre: 
14.29% 
N=2 
Post: 
7.69% 
N=1 
Pre: 
26.67% 
N=4 
Post: 
20% 
N=2 
 
Pre: 
21.43% 
N=3 
Post: 
7.69% 
N=1 
Pre: 
33.33% 
N=5 
Post: 
20% 
N=2 
Pre: 
14.29% 
N=2 
Post: 
23.08% 
N=3 
Pre: 
6.67% 
N=1 
Post: 
10% 
N=1 
8. I believe that 
if I receive the 
HPV vaccine, I 
will be 
protected 
against the 
most cancer-
causing strains 
of HPV. 
Pre: 
35.71% 
N=5 
Post: 
61.54% 
N=8 
Pre: 
43.75% 
N=7 
Post: 
72.73% 
N=8 
Pre: 
57.14% 
N=8 
Post: 
30.77% 
N=4 
Pre: 
31.25% 
N=5 
Post: 
27.27% 
N=3 
Pre: 
7.14% 
N=1 
Post: 
7.69% 
N=1 
Pre: 
12.50% 
N=2 
Post: 
0% 
N=0 
 Pre: 
6.25% 
N=1 
 Pre: 
6.25% 
N=1 
9.  I do not 
believe that 
HPV is 
exceptionally 
harmful. 
Pre: 
7.14% 
N=1 
Post: 
23.08%
N=3 
 
Pre: 
12.50% 
N=2 
Post: 
27.27% 
N=3 
Pre: 
21.43% 
N=3 
Post: 
23.08% 
N=3 
Pre: 
0% 
N=0 
Post: 
9.09% 
N=1 
 
 
Pre: 
7.14% 
N=1 
Pre: 
6.25% 
N=1 
Pre: 
42.86% 
N=6 
Post: 
46.15% 
N=6 
Pre: 
50% 
N=8 
Post: 
18.18% 
N=2 
Pre: 
21.43% 
N=3 
Post: 
7.69% 
N=1 
Pre: 
31.25% 
N=5 
Post: 
45.45% 
N=5 
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Qualitative Student Responses About the HPV Vaccine 
Age Group Responses 
18-20 yrs. Doesn’t sound like there are many downsides. 
 It can save you and others from getting cancer. 
 I received it when I was 15 and I think it’s a good thing to prevent rather 
than to cure. 
 I want to prevent any potential future problems.  
21-26 yrs. I believe that health care providers work to provide the public with safe 
vaccinations that help keep our population healthy.  
 It’s a vaccine. That prevents cancer. It’s so important. 
 Protection against cancer, duh! 
 Vaccines save lives! 
 
  
Questions Absolutely Agree 
(5pt) 
Agree 
(4pt) 
Neutral 
(3pt) 
Disagree 
(2pt) 
Absolutely Disagree 
(1pt) 
 Age 
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
Age  
18-20 
Age  
21-26 
10.  I do not 
have enough 
information 
about HPV 
and/or the HPV 
vaccine. 
Pre: 
14.29% 
N=2 
Post: 
30.77% 
N=4 
Pre: 
0% 
N=0 
Post: 
9.09% 
N=1 
Pre: 
21.43% 
N=3 
Post: 
7.69% 
N=1 
Pre: 
6.67% 
N=1 
Post: 
0% 
N=0 
Pre: 
28.57% 
N=4 
Post: 
15.38% 
N=2 
Pre: 
46.67% 
N=7 
Post: 
0% 
N=0 
Pre: 
21.43% 
N=3 
Post: 
15.38% 
N=2 
Pre: 
33.33% 
N=5 
Post: 
72.73% 
N=8 
Pre: 
14.29% 
N=2 
Post: 
30.77% 
N=4 
Pre: 
13.33% 
N=2 
Post: 
18.18% 
N=2 
11. My 
healthcare 
provider has 
offered to begin 
the HPV 
vaccine series 
for me.  
Post 
Only: 
58.33% 
N=7 
Post 
Only: 
83.33% 
N=5 
Post 
Only: 
16.67% 
N=2 
 Post  
Only: 
16.67% 
N=2 
   Post 
Only: 
8.33% 
N=1 
Post 
Only: 
16.67% 
N=1 
12. I am too 
busy with 
school/work/fri
ends to go see a 
healthcare 
provider. 
Post 
Only: 
7.69% 
N=1 
 Post 
Only: 
30.77% 
N=4 
  Post 
Only: 
9.09% 
N=1 
Post 
Only: 
30.77% 
N=4 
Post 
Only: 
72.73% 
N=8 
Post 
Only: 
30.77% 
N=4 
Post 
Only: 
18.18% 
N=2 
13. I intend to 
receive the 
HPV 
vaccination 
series in the 
future. 
Pre: 
28.57% 
N=2 
Post:  
57.14% 
N= 
Pre: 
16.67% 
N=1 
Post: 
66.67% 
N=2 
Pre: 
42.86% 
N=3 
Post: 
28.57% 
N= 
 Pre:  
28.57% 
N=2 
Pre: 
50% 
N=3 
Pre: 
0% 
N=0 
Post: 
14.29% 
N=1 
Pre: 
16.67% 
N=1 
Post: 
0% 
N=0 
 Pre: 
16.67% 
N=1 
Post: 
33.33% 
N=1 
14. I am 
motivated to 
maintain a 
healthy 
lifestyle. 
Pre: 
35.71% 
N=5 
Post: 
46.15% 
N=6 
Pre: 
43.75% 
N=7 
Post: 
72.73% 
N=8 
Pre: 
57.14% 
N=8 
Post: 
46.15% 
N=6 
Pre: 
43.75% 
N=7 
Post: 
27.27% 
N=3 
 Pre: 
12.50% 
N=2 
Pre: 
7.14% 
N=1 
Post: 
7.69% 
N=1 
   
15. My parents 
believe in 
receiving all 
vaccines, 
including the 
HPV vaccine. 
Post 
Only: 
84.62% 
N=11 
Post 
Only: 
81.82% 
N=9 
Post 
Only: 
15.38% 
N=2 
Post 
Only: 
9.09% 
N=1 
     Post 
Only: 
9.09% 
N=1 
16. My friends 
believe in 
receiving all 
vaccines, 
including the 
HPV vaccine.  
Post 
Only: 
53.85% 
N=7 
Post 
Only: 
45.45% 
N=5 
Post 
Only: 
38.46% 
N=5 
Post 
Only: 
27.27% 
N=3 
Post 
Only: 
7.69% 
N=1 
Post 
Only: 
18.18% 
N=2 
 Post 
Only: 
9.09% 
N=1 
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APPENDIX M. 3 AND 6 MONTH REASSESSMENT SURVEYS 
 
Questions Yes No Unsure/NA Total 
Students 
Did the human 
papillomavirus (HPV) 
education provided earlier in 
the year make you more 
likely to receive this vaccine? 
43% (N=4)   4 
Were you vaccinated with 
any part of the HPV vaccine 
series before the HPV 
education was given?  
86% (N=6) 14% (N=1)  7 
Have you made an 
appointment with Student 
Health Services or your 
healthcare provider to start 
the HPV vaccine series since 
receiving the HPV education? 
 43% (N=4) 14% (N=1) 
 
 
 
 
 
5 
Have you been vaccinated 
with at least 1 dose of the 
HPV vaccine series since 
receiving information about 
HPV? 
 71% (N=5)  5 
If not currently vaccinated for 
HPV, do you plan on 
receiving it in the future? 
29% (N=2)   2 
I was already fully vaccinated 
for HPV at the time of 
education.  
71% (N=5) 14% (N=1) 14% (N=1) 7 
I am not interested in 
receiving the HPV vaccine. 
 43% (N=3)  3 
I would like to receive more 
information about HPV and 
the HPV vaccine. 
43% (N=3) 57% (N=4)  7 
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Questions Yes No Unsure/NA Total 
Students 
Did the human papillomavirus 
(HPV) education provided 
earlier in the year make you 
more likely to receive this 
vaccine? 
43% (N=4)   4 
Were you vaccinated with any 
part of the HPV vaccine series 
before the HPV education was 
given?  
86% (N=6) 14% (N=1)  7 
Have you made an 
appointment with Student 
Health Services or your 
healthcare provider to start the 
HPV vaccine series since 
receiving the HPV education? 
 43% (N=4) 14% (N=1) 5 
Have you been vaccinated with 
at least 1 dose of the HPV 
vaccine series since receiving 
information about HPV? 
 71% (N=5)  5 
If not currently vaccinated for 
HPV, do you plan on receiving 
it in the future? 
29% (N=2)   2 
I was already fully vaccinated 
for HPV at the time of 
education.  
71% (N=5) 14% (N=1) 14% (N=1) 7 
I am not interested in receiving 
the HPV vaccine. 
 43% (N=3)  3 
I would like to receive more 
information about HPV and the 
HPV vaccine. 
43% (N=3) 57% (N=4)  7 
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APPENDIX N. EXECUTIVE SUMMARY OF THE PROJECT 
The purpose of this disquisition was to determine knowledge, beliefs, attitudes, and 
barriers of college-age students at North Dakota State University (NDSU) related to the human 
papillomavirus (HPV) and the vaccine used to prevent certain strains of the virus.  HPV is the 
most common sexually transmitted infection in the United States, with the highest rates of 
infection occurring in the late teens to early twenties (CDC, 2015b).  Therefore, there is a need to 
educate college age students about HPV and how to protect themselves from acquiring it.  An 
intervention was designed to address the following clinical question: Will the provision of HPV 
education to college students, ages 18-26, increase HPV knowledge, vaccine intent, and the 
number of student HPV vaccinations within six months at NDSU?  Four practice improvement 
project objectives were designed to determine the overall success of the project. They are listed 
as follows: 
• Practice Improvement Objective One – Determine whether an educational video 
intervention can successfully improve HPV knowledge among NDSU students. 
• Practice Improvement Objective Two – Determine whether an educational video 
intervention can successfully improve HPV vaccination intent and vaccine uptake among 
NDSU students. 
• Practice Improvement Objective Three – Assess NDSU student beliefs, attitudes, and 
barriers associated with the HPV vaccine.  
• Practice Improvement Project Objective Four: Provide HPV education to NDSU student 
participants at the annual spring Sex Positivity Expo). 
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The project intervention consisted of two components: reaching out to NDSU students at 
the annual Sex Positivity Expo, and providing education to members of two NDSU 
organizations, the Women’s Activist Organization (WAO), and Violence Prevention Educators 
(VPE).  A booth was set up at the annual Sex Positivity Expo (SPE), hosted by the WAO, where 
students could stop by, receiving education and asking questions about HPV.  They were first 
invited to take part in the online pre-and post-survey.  If they declined to be part of the study, 
education and questions were then addressed. During the SPE, a total of 55 students stopped by 
the HPV education booth and either visited about what questions they had, or were emailed a 
link to participate in the pre-and post-survey.  Meeting times for HPV education were also set up 
with members of WAO and VPE at designated organization meeting times. The WAO meeting 
took place on April 5, 2017 in the Rose Room in Memorial Union, and the VPE meeting took 
place on April 11, 2017 in a classroom on the third floor of the Family Life Center.   Students 
were first instructed to take an online Qualtrics pre-survey to establish baseline HPV knowledge, 
beliefs, attitudes, and barriers.  Following the pre-survey, students were instructed to watch a 
short educational video about HPV and the HPV vaccine, and then complete a similar post-
survey to assess if there were increases in basic HPV education, and changes in beliefs, attitudes, 
barriers, or intent to vaccinate.  At three and six months after participating in the initial education 
session, consenting students were then sent a reassessment Qualtrics survey link to determine 
any increases in vaccination rates or intent to vaccinate. 
A total of 14 online pre-and post-surveys were started by SPE participants, and eight 
were completed.  A total of 11 surveys were started by WAO participants, and nine were 
completed.  A total of nine surveys were started by VPE participants, and eight were completed. 
The different topics which were assessed in pre-and post-surveys include the following: student 
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health data, HPV knowledge, HPV beliefs/barriers/attitudes, current vaccination status, and 
intent to vaccinate. Results between pre-and post-survey data indicated an increase in both HPV 
knowledge and intent to vaccinate.  An increase in vaccination rates was not noted, although of 
the 30 student participants, 70% had either partially or fully completed the HPV vaccine series 
prior to education. Questions addressing attitude indicated an increase in motivation to maintain 
a healthy lifestyle.  Questions addressing belief indicated students believed they would be 
protected from the most cancer-causing strains of HPV. Fifty percent of students indicated they 
believed themselves at risk for acquiring HPV.  Questions addressing barriers indicated the 
following were not barriers:  healthcare coverage, work and school, and their provider offering 
them the chance to begin the HPV vaccine series.  The only barrier identified with a slight 
increase in mean of 0.08 indicated the cost of the vaccine series to be a concern. 
The results of the three and six-month surveys were identical to each other in all question 
responses. Results revealed four of seven respondents were more likely to receive the HPV 
vaccine. Six of seven students were already vaccinated with at least part of the HPV vaccine 
series, and one student was not.  Four students stated they had not made an appointment to 
receive the HPV vaccine, and one student was unsure.  Five students answered they had not 
received any HPV vaccination since the education session, and five had indicated they were 
already fully vaccinated.  Two students indicated they do intend to receive the vaccine in the 
future. Three students disagreed they were not interested in receiving the HPV vaccine, and three 
students indicated they would like more information about the HPV vaccine. If the student 
indicated they would like more vaccine information, a link to a CDC website discussing the HPV 
vaccine then appeared on their screen.  
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Qualitative data was also collected.  An open-ended question at the end of the post-survey 
allowed students to type in a response about why they did or did not believe in the HPV vaccine. 
The follow responses were recorded: 
• Doesn’t sound like there are many downsides. 
• It can save you and others from getting cancer. 
• I received it when I was 15 and I think it’s a good thing to prevent rather than to cure. 
• I want to prevent any potential future problems. 
• I believe that health care providers work to provide the public with safe vaccinations that 
help keep our population healthy. 
• It’s a vaccine. That prevents cancer. It’s so important. 
• Protection against cancer, duh! 
• Vaccines save lives! 
Program success was evaluated by going through each objective to decide if they were 
“met”, “partially met”, or “unmet”.  Objectives one, three, and four were deemed to be “met”, 
while objective two was deemed to be “partially met” due to the lack of increase in vaccine 
uptake. An additional evaluation question at the end of the post-survey asked students how 
reliable they found the information presented to them in the video.  Question responses included 
“Very Reliable”, “Reliable”, “Slightly Reliable”, and “Not at All Reliable”.  Eighteen students 
(60%) rated the video information as “Very Reliable”, six (20%) rated it as “Reliable”, and one 
(3%) rated it as “Slightly Reliable”.  Overall, this was a good response to the education, as the 
majority of students gave it the highest possible rating.  
 
 
